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ABSTRACT 
 Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the 
quality of life of millions of patients worldwide.  This disease is associated with 
inflammation and ulceration of the colonic epithelium, leading to an increased risk for the 
development of UC-associated colorectal cancer (CRC).  Current UC medications are 
designed to manage the symptoms and induce remission; however, several challenges are 
faced with current treatment options.  5-aminosalicyclic acid and corticosteroids have few 
side effects, but have limited efficacy and often the disease becomes refractory.  Biologics 
are introduced after initial treatments fail, but serious side effects are often associated with 
these medications.  In the hope of developing a safe and effective UC therapeutic, we are 
testing a small molecule inhibitor of Protein Arginine Deiminases (PADs), which are 
implicated in many inflammatory diseases, like Alzheimer’s disease, Multiple Sclerosis, 
Rheumatoid Arthritis, and UC. 
 PADs catalyze the conversion of peptidyl-Arginine to peptidyl-Citrulline through 
a process termed ‘citrullination’.  Chlor-amidine (Cl-amidine) is designed to irreversibly 
inhibit PADs through covalent modification at the active site of the enzymes.  Our initial 
studies have determined that Cl-amidine is generally nontoxic in cell and animal models.  
Next, we tested the efficacy of Cl-amidine in the HCT116 colon cancer cell line and the 
Azoxymethane (AOM)/Dextran Sulfate Sodium (DSS) murine model of UC.  We showed 
that Cl-amidine effectively reduced inflammation, oxidative stress produced by activated 
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leukocytes, and DNA damage.  Based on these findings, we hypothesized that Cl-amidine 
could prevent the progression to UC-associated CRC.  In vitro studies indicated that Cl-
amidine may act as a tumor suppressor by upregulating miR-16, a putative tumor 
suppressor miRNA with cell cycle targets, and causing G1 cell cycle arrest.  Our results 
showed that in the AOM/DSS murine model of UC-associated CRC, Cl-amidine 
significantly inhibited tumorigenesis, further supporting our hypothesis. 
 For a mechanistic study of Cl-amidine, we explored the idea that Cl-amidine may 
be preventing the citrullination and/or hyperactivity of DNA methyltransferases (DNMTs).  
Hypermethylation is reported to cause methylation-mediated gene silencing; therefore, we 
postulated that PADs may be citrullinating DNMTs and causing hypermethylation of genes 
regulating tumor suppressor miRNAs.  We verified that DNMTs can be citrullinated and 
that the inhibition of DNMTs or PADs restores miR-16 levels to comparable levels.  Cl-
amidine also reduced the methylation of the miR-16 promoter as effectively as DNMT 
inhibition.  Ultimately, the objective of our research is to provide evidence of nontoxic and 
more successful treatment options for UC. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 GENERAL OVERVIEW 
 Acute inflammation is the body’s natural response to foreign pathogens, damaged 
cells, and other exogenous stimuli.  The purpose of inflammation is to rid the body of these 
irritants and prevent any damage to cells and tissue.  To kill or isolate the source of the 
inflammatory response, several factors are involved in inflammation, including 
vasodilation, immune cell infiltration, and the release of pro-inflammatory cytokines (1-3).  
Vasodilation increases blood flow and subsequent migration of pro-inflammatory immune 
cells (e.g. macrophages and neutrophils), which also can result in swelling, redness, and 
tenderness at the site of inflammation (3).  Since inflammation triggers an innate immune 
response, pro-inflammatory immune cells release pro-inflammatory cytokines.  Cytokines, 
like inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2), are released to 
induce DNA damage and ultimately kill invading pathogens, allowing for cell and tissue 
damage to be repaired (4, 5). 
 Persistent infections or abnormal immune responses can cause chronic 
inflammation, which can lead to more serious diseases.  Chronic and acute inflammation 
trigger an immune response; however, as the duration of inflammation increases, 
insufficient repair and regeneration begins to affect surrounding normal cells and tissue.  
Chronic inflammatory diseases, like Rheumatoid arthritis (RA) and Ulcerative colitis (UC), 
are marked by inflammatory cell infiltration, high levels of pro-inflammatory cytokines, 
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and tissue damage (6-8).  Certain chronic inflammatory diseases, including UC, increase 
the risk for the development of tumors in the affected areas (9, 10).  Cancers arising from 
chronically inflamed tissues differ from sporadic cancers, but share many cancer hallmarks, 
such as uncontrolled cell growth and decreases in tumor suppressors.  In UC-associated 
colorectal cancer (CRC), tumor suppressors that regulate the cell cycle [i.e. p53 and 
microRNAs (miRNAs)] are frequently mutated or deleted (11-15).  UC and UC-associated 
CRC are also associated with increased levels of Protein Arginine Deiminases (PADs) (7, 
16, 17).  PADs are a family of enzymes that catalyze citrullination, the conversion of 
peptidyl-Arginine to peptidyl-Citrulline (18, 19).  PADs are inflammation-dependent 
enzymes since they are present in neutrophils and macrophages and are often activated in 
inflammatory environments (20, 21).  An introduction to the roles Protein Arginine 
Deiminases (PADs) play in physiological and pathological conditions, as well as the 
development and current uses of PAD inhibitors, will be discussed in Chapter 2 (22). 
 Our studies have used Chlor-amidine (Cl-amidine) to study the effects of PAD 
inhibition.  Upon inhibiting PADs, we have shown decreased levels of inflammation, 
oxidative stress, and DNA damage associated with UC (7, 8).  Likewise, subsequent 
inhibition of tumorigenesis, alongside increases in tumor suppressors, results from Cl-
amidine treatment in our cell and animal models of UC-associated CRC (23, 24).  An 
epigenetic study was carried out to further explore and understand how Cl-amidine and 
PAD inhibition are functioning to prevent the development of tumors in UC-associated 
CRC.  The overall purpose of this dissertation is to prove the efficacy and uncover the 
mechanisms of action of Cl-amidine by testing this novel therapeutic in models of UC and 
UC-associated CRC. 
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1.1.1 ULCERATIVE COLITIS 
 Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease (IBD) 
that affects approximately 865,000 patients in North America.  Each year there are nearly 
70,000 new cases in the United States and Canada alone.  Northern Europe also has similar 
incidence and prevalence rates (25).  UC affects patients usually between the ages of 15 
and 30, but the disease has a secondary peak between the ages of 50 and 70 years (25).  The 
disease is characterized by inflammation of the mucosa of the large intestine with clinical 
symptoms of rectal bleeding, pain, and diarrhea (26).  It is generally unknown what causes 
UC, but environmental factors, genetics, and abnormal immune responses are thought to 
play major roles in the development of the disease (25, 26).  
 Since UC is associated with autoimmunity and inflammatory dysregulation, there 
are various treatment strategies available.  The first line of treatment for mild to moderate 
cases of UC is to prescribe anti-inflammatory drugs, such as 5-aminosalicyclic acid (5-
ASA) or corticosteroids.  To combat the inflammatory response, 5-ASA works as an anti-
oxidant, while corticosteroids suppress the hyperactive immune system (25, 26).  
Unfortunately, 5-ASA is often ineffective or may take four weeks or more to achieve 
remission (27).  Similarly, corticosteroids can have only temporary effects; therefore, more 
potent (and immunosuppressive) options are available.  Biologics that inhibit inflammatory 
targets, for instance tumor-necrosis factor-α (TNF-α), are available after initial treatments 
are refractory and unsuccessful at inducing remission of active UC (28).  However, 
biologics, including adalimumab (Humira), are associated with dangerous side-effects 
(28).  For severe cases of UC, partial or complete surgical removal of the colon is 
necessary; yet, this is used as a last resort when other treatment strategies have failed (29).  
 4 
Understanding the fundamental processes that initiate and perpetuate the active disease 
state of UC is important to develop safer and more effective alternatives to the current 
therapeutics. 
1.1.1.1 INFLAMMATION 
 There are several key features that contribute to the severity and progression of UC.  
The aberrant immune response at the onset of UC leads to the release of pro-inflammatory 
cytokines.  Nevertheless, (controlled) inflammation is a natural, regulatory process in 
response to certain stimuli.  iNOS and Cox-2, key pro-inflammatory cytokines, are 
regarded as universal indicators of active UC and their expression levels correlate to the 
severity of the disease (30-36).  iNOS is an enzyme that converts L-Arginine to nitric oxide 
(NO) and is associated with the inflammatory response (2).  NO is an important signaling 
molecule with various effects (e.g. vasodilation (37, 38), immune response (1)).  NO is 
released by stimulated inflammatory cells (e.g. macrophages, monocytes, neutrophils) as a 
free radical causing lethal DNA damage in invading pathogens (4, 39).  Cox-2, an enzyme 
that converts arachidonic acid into prostaglandins, also works by regulating inflammation 
and is normally only expressed in cells involved in an inflammatory response (2, 5).  
Additionally, inflammation is regularly associated with elevated calcium levels due to 
activated signal transduction cascades and the release of calcium from apoptotic cells (40-
42); subsequently, calcium-dependent molecules and processes see a spike in activity.  
PADs, which catalyze the citrullination of peptidyl-Arginine to peptidyl-Citrulline, are an 
example of calcium- and inflammation-dependent enzymes that have physiological 
functions to promote apoptosis (20, 43). 
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 Under prolonged inflammatory conditions associated with UC, physiological 
inflammatory processes become dysregulated, resulting in various deleterious events, 
including oxidative stress and the accumulation of DNA damage caused by NO and other 
free radicals produced by inflammatory cytokines (4, 39, 44).  Additionally, Cox-2 
upregulation is found in CRC (45) and PADs/excessive citrullination are implicated in 
chronic inflammatory diseases where elevated calcium levels remain for extended periods 
(see Chapter 2 for further discussion concerning PADs and inflammatory diseases).  These 
examples further demonstrate how the maintenance of the inflammatory response is 
essential to avoid tipping the balances towards pathological inflammation. 
1.1.1.2 OXIDATIVE STRESS AND DNA DAMAGE 
 In response to the inflammatory environment, leukocytes infiltrate and produce 
reactive oxygen and nitrogen species (RONS) to attack stimuli (46).  RONS that are 
produced by pro-inflammatory leukocytes include: superoxide anions (•O2-), hydroxyl 
radicals (•OH), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-) (47-49).  
Superoxide dismutase 1 (SOD1), Glutathione peroxidase 1 (GPx1), and catalase are 
important enzymes that catalyze free radicals into stable molecules (50-52).  SOD1 targets 
and converts superoxide anions to hydrogen peroxide and oxygen molecules.  
Subsequently, GPx1 and catalase function by reducing hydrogen peroxide to more steady 
water and oxygen molecules.  
 The presence of RONS leads to oxidative stress if antioxidant defenses are impaired 
(53).  Typically antioxidant enzymes (e.g. SOD1, GPx1, and catalase) are detrimentally 
repressed in UC, driving oxidative stress (54-57).  Then, upon prolonged exposure to 
oxidative stress, DNA damage can occur (10, 44, 58).  Single-strand breaks (SSBs) 
 6 
commonly result from oxidative stress, but when multiple SSBs occur close by on 
complementary strands of DNA, double-strand breaks (DSBs) can occur (59, 60).  The 
buildup of unrepaired DNA breaks can result in improper DNA replication with mutations 
in critical tumor suppressors, oncogenes, and repair genes, ultimately leading to the 
initiation of carcinogenesis (61). 
1.1.2 ULCERATIVE COLITIS-ASSOCIATED COLORECTAL CANCER 
 There are several inflammatory diseases that are known to increase the patients’ 
risk of developing malignancies at the sites of chronic inflammation, including Barrett’s 
esophagus (esophageal cancer) (62, 63), pancreatitis (pancreatic cancer) (64, 65), and 
hepatitis (liver cancer) (66, 67).  Comparably, due to the chronic inflammatory state of UC, 
patients suffering from UC are at a high risk of developing colorectal cancer (CRC).  
Approximately 20% of UC patients will develop CRC as the risk increases yearly (9).  In 
recent years, CRC was predicted to cause 50,000 deaths yearly, making CRC the second 
leading cause of cancer-related deaths (in both men and women) in the United States (68).  
Once UC-associated CRC is detected, treatments options include surgery to remove the 
dysplasia/tumorigenic areas (69, 70).  However, since UC patients have the heightened 
potential of developing CRC, there are several cancer preventative strategies available, 
including scheduled colonoscopies to monitor the extent of UC and to ensure that CRC has 
not manifested (71, 72).  Similarly, current treatments of UC act as chemopreventatives by 
inhibiting potentially tumorigenic processes, only if remission is achieved and sustained.  
The prevalence and mortality of CRC, even with current treatment options, further 
substantiates the need for a successful and nontoxic UC treatment. 
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1.1.2.1 CELL PROLIFERATION AND THE CELL CYCLE 
   The cell cycle is divided into 4 active phases: Gap 1 (G1), Synthesis (S), Gap 2 
(G2), and Mitosis (M).  In G1 and G2, cells are growing in order to accommodate DNA 
replication (S phase) and cell division (M phase) (73).  There are checkpoints at G1/S and 
G2/M to ensure that the cellular genome is stable and that cells are properly prepped to 
divide (74).  The G1 checkpoint is important to prevent the replication of aberrant DNA 
sequences in cells with damaged DNA (75).  Also, to progress through G1 to S, a series of 
interactions between cyclins and cyclin-dependent kinases (Cdks) are necessary.  Cyclin D 
and Cyclin E are key cyclins in G1/S that correspond to Cdk4/6 and Cdk2, respectively 
(76).  These interactions must both occur sequentially to fully phosphorylate 
retinoblastoma (Rb) protein and activate transcription factors that progress the cell through 
G1 to S (77).  Since the cell cycle requires Cyclin D-Cdk4/6 and Cyclin E-Cdk2 to advance, 
cyclin and Cdk inhibitors can induce cell cycle arrest in response to stress (e.g. genomic 
and oxidative stress) (78, 79).  In cancer, these cell cycle monitors are frequently 
dysregulated, making increased or uncontrolled cell proliferation one of the hallmarks of 
cancer (80).  Therefore, the development of therapeutic cell cycle inhibitors is a noteworthy 
anti-cancer approach. 
1.1.2.2 P53 AND TUMOR SUPPRESSION 
 p53 is widely accepted as a tumor suppressor or even the “guardian of the genome” 
(81) and can be activated in response to certain stimuli, such as oxidative stress and DNA 
damage (82, 83).  Upon stimulation by stressors, p53 becomes post-translationally 
modified (typically by phosphorylation (84) or acetylation (85, 86)), which increases the 
half-life and accumulation of p53 (87, 88), and becomes localized in the nucleus.  Once in 
 8 
the nucleus, p53 can transcriptionally trigger cell cycle arrest at the G1/S checkpoint to 
allow for DNA repair.  The genes encoding for p21WAF/Cip1, a Cdk inhibitor, and growth 
arrest and DNA damage protein 45 (GADD45) are the main cell cycle targets of p53 that 
prevent the damaged cells from leaving G1 and entering S phase (89-92).  Alongside cell 
cycle arrest, p53 can activate the DNA mismatch repair gene MLH1 in response to DNA 
damage (93).  However, in situations where the damaged DNA is irreparable, p53 can 
initiate apoptosis by inducing its pro-apoptotic targets, including p53 upregulated 
modulator of apoptosis (PUMA) (94), p53 apoptosis-inducing protein 1 (p53AIP1) (95), 
and Bcl-2 associated X protein (Bax) (96). 
 When p53-dependent pathways are no longer needed, a ubiquitin ligase MDM2 
binds to and ubiquitinates p53, designating p53 for degradation in the cytoplasm (97).  
MDM2 regulates p53-induced cell cycle arrest and apoptosis (98, 99), but MDM2 is also 
considered oncogenic since its overexpression can inhibit p53 function in genotoxic 
conditions (100, 101).  p53 stability and functional maintenance are essential to avoid 
cancer development resulting from genomic aberrations; yet, p53 activity is diminished 
during the early stages of UC-associated CRC versus the late stages of sporadic CRC (13, 
102, 103).  Likewise, p53 variations (i.e. mutations or deletions) are reported in 
approximately 85% of UC-associated CRC cases (11, 12).  With all of the regulatory 
targets of p53, it is evident the dire consequences that p53 deletion and/or loss of function 
can have in pathological conditions, like UC and UC-associated CRC.  
1.1.2.3 MICRORNA 
 As a mechanism of tumor suppression, microRNAs (miRNAs or miRs) are short 
non-coding RNA sequences that work post-transcriptionally to silence target genes.  There 
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are several steps and key machinery involved in the biogenesis of mature miRNAs.  
Briefly, the initial RNA transcripts of miRNA commonly fold into short hairpin/stem-
loops.  The sequence of several different mature miRNAs can be found within these 
primary miRNA (pri-miRNA) structures; nevertheless, the generation of specific mature 
miRNAs is dependent on the processing.  Pri-miRNAs are cleaved in the nucleus by the 
RNase Drosha to form precursor miRNA (pre-miRNAs) (104).  Upon export from the 
nucleus to the cytoplasm by Exportin-5 (105), the loop of the pre-miRNA is cleaved by 
Dicer with subsequent strand cleavage (106-108).  Mature miRNAs are then incorporated 
into a RNA-induced silencing complex (RISC) where the miRNA binds to the 3’ 
untranslated region (UTR) of messenger RNAs (mRNAs) that share a complementary 
sequence (109).  MiRNAs that silence tumor-promoting genes are tumor suppressor 
miRNAs, while miRNAs that silence anti-cancer genes are termed onco-miRs.  MiRNA 
expression, depending on gene targets, can affect cancer initiation, development, and 
metastasis.  The expression profiles of many tumor suppressor miRNAs are downregulated 
in tumor tissue as compared to normal adjacent or healthy tissue.  Examples of 
downregulated miRNAs in cancer include: miR-16 in leukemia, breast, and colon cancer 
(15, 110, 111); miR-200b in gastric, breast, liver cancer (112-114); and miR-195 in cervical 
and bladder cancer (115, 116). 
 MiR-16 is a putative tumor suppressor miRNA with cell cycle targets, including 
Cyclin D1/E1 and Cdk6 (23, 117-120).  Typical of miRNAs encoded in intronic regions, 
miR-16 expression is regulated by its host gene DLEU2 (110, 121).  As examples of host 
gene expression affecting miR-16 expression, chronic lymphocytic leukemia (CLL) 
patients frequently have DLEU2 deletions with subsequent miR-16 deletion (110).  
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Meanwhile, in instances of cancer where DLEU2 is not genomically lost, miR-16 
expression can be downregulated due to aberrations in the DLEU2/miR-16 promoter (122, 
123).  Alternatively, abnormalities in miRNA processing can affect miRNA maturation 
(124, 125).  For instance, p53 is known to interact with Drosha to promote maturation of 
miRNAs, including miR-16 (124).  Since p53 is mutated or deleted in about 85% of cases 
of UC-associated CRC (11, 12), this provides additional foundation for the prevalence of 
miR-16 downregulation in UC-associated CRC. 
1.1.2.4 DNA METHYLTRANSFERASES (DNMTS) 
 In addition to expression changes in miRNAs, aberrant DNA methylation is another 
common epigenetic feature of UC-associated CRC (126).  The DNMTs are a family of 
enzymes that catalyze the addition of methyl groups to cytosines.  The enzymatically active 
members of the DNMT family include the abundant maintenance methyltransferase, 
DNMT1, and de novo methyltransferases, DNMT3A and DNMT3B (127).  DNMT1 only 
methylates hemi-methylated substrates, while DNMT3A and DNMT3B do not exhibit a 
preference for hemi-methylated substrates (128).  CpG dinucleotides are most commonly 
the targets of DNA methylation with promoter methylation often resulting in gene silencing 
(129).  This gene silencing could possibly lead to carcinogenesis if the silenced gene is a 
tumor suppressor (130-132).  In the case of miR-200b, hypermethylation of its host gene 
promoter can even trigger methylation-mediated gene silencing of miRNAs (133).  In UC 
patient samples, there are several genes that are also repressed by promoter 
hypermethylation, such as the DNA mismatch repair gene MLH1 (134) and the cell cycle 
inhibitor p16INK4a (135).  With the substantial involvement of DNMTs in the epigenetic 
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regulation of tumor suppressors, preventing hypermethylation is a potential UC-associated 
CRC therapeutic avenue. 
1.2 IN VITRO MODELS 
 For the in vitro models used to study inflammation, oxidative stress, cell 
proliferation, and epigenetics, we used immortalized human colorectal cancer and mouse 
macrophage cell lines.  HCT116 human colorectal cancer cells were used as a model for 
colonic epithelial cells, which are the cells that become pro-cancerous in colon carcinomas 
(136, 137).  HCT116 wild-type (HCT116wt) cells are p53 proficient, but there are isogenic 
lines of HCT116 cells that have been constructed to be p53 deficient (HCT116 p53-/-), 
DNMT1 deficient (HCT116 DNMT1-/-), and DNMT3B deficient (HCT116 DNMT3B-/-
).  The HCT116 cells were used in studies to investigate DNA damage resulting from 
inflammatory and oxidative stress, measure p53-dependent expression of miRNAs and 
their targets, and explore epigenetic mechanisms of gene regulation.   
 For inflammatory and oxidative stress studies, ANA-1 murine macrophage cells 
were used to represent inflammatory cells as would be harvested from animal models of 
inflammation.  ANA-1 cells can be stimulated/activated with interferon-gamma (IFN-γ) to 
produce an inflammatory response, including the release of cytokines (e.g. iNOS, COX-2, 
etc.).  When HCT116 and activated ANA-1 cells are cocultured, this produces an 
inflammatory environment for the HCT116 cells, which simulates the environment that 
colonic epithelial cells are exposed to during periods of active inflammation in UC.  
HCT116 and activated ANA-1 cells were separated after coculture using CD45+ magnetic 
microbeads.  CD45 is a cell surface marker found on all leukocytes; therefore, ANA-1 cells 
are CD45+ and HCT116 cells are CD45- (138).  The coculture experiments were designed 
 12 
as a model to study the effects of inflammation and oxidative stress on isolated epithelial 
cells. 
 In our experiments using PAD inhibitors (i.e. Cl-amidine), it is important to explain 
that HCT116 cells exhibit a basal level of citrullination.  Meanwhile, different cell lines 
used by other groups to study the effects of citrullination require induction with calcium 
ionophores (e.g. HL-60 and HEK 293) or stimulation with lipopolysaccharide (e.g. 
RAW264.7) to detect citrullinated proteins (139, 140).  Since HCT116 cells do not require 
induction of citrullination, PAD inhibitors can be administered directly to untreated cells, 
eliminating the risk of off-target results caused by the influx of calcium into the cell 
associated with calcium ionophore treatment.  This makes HCT116 cells an ideal model 
for studying citrullination, especially in UC and UC-associated CRC.   
 We used HCT116 (wt, DNMT1-/-, and DNMT3B-/-) cells as our in vitro model of 
epigenetic regulation of miRNA.  HCT116 cells are a suitable model for studying the 
effects of hypermethylation caused by DNMTs because they are susceptible to 
methylation-mediated gene silencing (141, 142).  
 In vitro cellular models are suitable models for isolating the effects of 
pharmacological compounds; however there are several limitations of in vitro UC and CRC 
models.  In vitro models do not reflect all of stages involved in the progression from 
inflammation to tumor initiation to metastasis (143), nor do they completely represent all 
of the complex pathways that are involved and interact in in vivo models.  Therefore, 
several in vivo animal models have been developed to enable the study of premalignant 
and malignant stages of CRC.  These models, which can be used to study therapeutic and 
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preventative capabilities of a compound, also are reliable with consistent and reproducible 
results.  
1.3 IN VIVO MODELS 
 Multiple in vivo animal models of UC and CRC have been established using 
genetic, xenograft, and chemically-induced methods with rodents of different background 
strains.  These models can be used to study inflammation (without the presence of tumors), 
inflammation-associated tumorigenesis, and sporadic tumorigenesis.  For our in vivo 
studies, we used the azoxymethane (AOM)/ dextran sodium sulfate (DSS) murine models 
of UC and UC-associated CRC.  AOM is a genotoxic, carcinogenic agent that is given via 
a single intraperitoneal (i.p.) injection at the initiation of the experiment.  DSS is a non-
genotoxic agent and is thought to cause colitis by disrupting tight junctions between colon 
epithelial cells, which in turn increases the permeability of the gut barrier.  Although the 
precise mechanism of action of DSS is unknown, DSS causes irritation to the colonic 
epithelial cells that stimulates an inflammatory response (144).  We used 8-12 week old 
C57BL/6 male mice in all of our in vivo models because this strain has proven susceptibility 
to DSS-induced colitis (145).  To note, all male mice were used in our studies because DSS 
is shown to have lower efficacy in female mice, perhaps due to estrogen levels interfering 
with the action of DSS (146).  DSS is administered in the drinking water in cycles 
throughout the experiment.  The experimental treatment schedule and duration are 
dependent on the endpoint to be studied.  Hence, experiments aimed at treating UC require 
a shorter duration than experiments aimed at preventing CRC.  
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1.3.1 AOM/DSS MOUSE MODEL OF ULCERATIVE COLITIS 
 The DSS murine model of UC is a common model because it shares a comparable 
etiology, pathogenesis, and clinical outcome to human UC (147).  In our animal model of 
acute UC, we included the single i.p. injection of AOM as an experimental control since 
our UC-associated CRC model also required the initial AOM injection.  As verified by our 
results, AOM alone did not cause inflammation, nor did it induce tumorigenesis (when 
given with DSS) in short-term experiments.  DSS and Cl-amidine treatments began 7 days 
after the AOM injection and lasted for 14 days.  DSS and Cl-amidine (see Chapter 2 for 
background regarding Cl-amidine) were both administered to the mice in the drinking 
water and were refreshed every 2 days to ensure stability of the compounds (Figure 1.1).  
This short-term model imitates the continuous injury to the colon resulting from the 
inflammatory state of UC and allows us to test our compound for therapeutic properties.   
1.3.2 AOM/DSS MOUSE MODEL OF ULCERATIVE COLITIS-ASSOCIATED COLORECTAL 
CANCER 
 The principle behind the AOM/DSS model of UC-associated CRC is that prolonged 
exposure to damaging inflammation and oxidative stress leads to DNA damage, which 
ultimately results in tumorigenesis.  The carcinogenic initiation by AOM and promotion 
by DSS allows for tumors to appear within 10 weeks after the AOM injection, as compared 
to the 30 weeks it would take for mice given AOM alone to develop tumors (148).  In 
addition to the substantially decreased time for tumor development, the AOM/DSS model 
of CRC is widely used because it demonstrates a sequence of events that are distinct to 
inflammation-driven CRC, as compared to sporadic CRC (13).  For instance, pro-
inflammatory cytokines (e.g. TNF, IFN-γ, NF-κB) increase and p53 levels decrease at early 
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stages of UC-associated CRC, while inflammatory cytokines are not typically elevated and 
p53 changes do not occur until the final stage of sporadic CRC (13, 102, 103). 
 For our AOM/DSS murine model of UC-associated CRC, we began cycles of DSS 
and Cl-amidine treatments 7 days and 14 days, respectively, after the initial AOM i.p. 
injection and concluded on Day 70 of the experiment.  Cycles of DSS consisted of DSS 
given for 7 days, followed by 14 days of normal drinking water.  These cycles were meant 
to mimic the inflammatory state of the active disease with periods of remission.  At Day 
35 (midpoint of the experiment), mice had not developed tumors, but, as expected, 
inflammation and ulceration was significant in the mice given only DSS.  This long-term 
model of UC-associated CRC allows us to replicate cycles of relapsing, chronic 
inflammation and measure the events preceding (Day 35) and during (Day 70) 
tumorigenesis. 
1.4 OBJECTIVE OF THE RESEARCH 
 Over the past 50 years, investigators have tried various approaches with numerous 
targets to treat UC.  Treatments are designed to either treat the symptoms of the active 
disease or induce remission by targeting the underlying causes of UC.  These approaches 
include: pro-inflammatory cytokine inhibitors, immunomodulators, and free radical traps.  
Currently the most common treatment options for UC are: 5-ASA, corticosteroids, and 
TNF-α monoclonal antibodies/biologics (25, 26).  Unfortunately, current treatments for 
UC do not have optimal results in patients.  For instance, 5-ASA is a relatively safe option 
since it has local effects on the colon, but 5-ASA only has marginal outcomes in UC 
patients.  To increase potency, consequentially, safety is often sacrificed.  Such as, Humira, 
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the FDA-approved TNF-α inhibitor, is immunosuppressive with a substantial list of 
possible, deleterious side effects (e.g. infection, heart failure, skin cancer) (149-151). 
 The development of an effective treatment (without the negative side effects) is the 
aim of many current studies in the IBD field, especially with the link connecting the 
extended duration of UC to the considerable increased risk of UC-associated CRC.  Even 
if UC-associated CRC does not occur, UC causes a significant decrease in the affected 
patient’s quality of life due to the chronic persistence of the disease.  For these reasons, the 
hunt for novel safe and effective therapeutics towards the cure of UC is crucial.  With this 
as a goal of our research, we evaluated the potential of Cl-amidine as a therapeutic 
compound to treat UC in Chapter 3.  We translated our in vitro inflammatory models to an 
in vivo murine model of UC and saw that Cl-amidine inhibited the key steps that cause the 
progression from an abnormal immune response within the colon to UC-associated CRC 
(Chapter 3).  To build off of our successful results showing that Cl-amidine suppresses UC 
in our models, we tested Cl-amidine as a chemopreventative compound in our UC-
associated CRC models (Chapter 4).  Also in Chapter 4, we verified a mechanism of action 
where the tumor suppressor miR-16 and its cell cycle targets are upregulated upon Cl-
amidine treatment in vivo.  To further understand how Cl-amidine is targeting specific 
miRNAs, Chapter 5 explores the epigenetic mechanism of Cl-amidine in regards to its 
ability to prevent methylation-mediated gene silencing of tumor suppressor miRNAs that 
are typically downregulated in cancer.  Since we have determined several mechanisms of 
action for Cl-amidine and have proven its efficacy against UC and UC-associated CRC, 
Chapter 6 concludes with a summary of the research project and the future directions to be 
pursued. 
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1.5 SPECIFIC AIMS 
 A schematic diagram of this project, including specific aims and results, is provided 
in Figure 1.2.  Below, individual aims are described: 
Specific Aim 1: To determine the therapeutic efficacy of Cl-amidine in our in vitro and in 
vivo models of UC (Chapter 3). 
Specific Aim 2: To determine the preventative efficacy of Cl-amidine in our in vitro and 
in vivo models of UC-associated CRC (Chapter 4). 
Specific Aim 3: To understand the epigenetic mechanisms of Cl-amidine in vitro (Chapter 
5). 
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FIGURES 
 
 
 
Figure 1.1. Cl-amidine is stable in water and DSS for 48h.  As measured by mass 
spectroscopy by the lab of Dr. Paul Thompson, Cl-amidine remains relatively stable in 
water for A) 24h and B) 48h and in DSS + water for C) 24h and D) 48h.  Arrows indicate 
the peaks for Cl-amidine. 
  
 
1
9
 
 
 
 
Figure 1.2. Outline of specific aims.  Aim 1 will test the efficacy of Cl-amidine to suppress the hallmarks of UC (i.e. inflammation, 
oxidative stress, and DNA damage).  Aim 2 will test if Cl-amidine can prevent UC-associated CRC and will uncover potential 
mechanisms of action.  For a further mechanistic study, Aim 3 will explore how Cl-amidine may epigenetically regulate miRNA 
promoters by preventing methylation-mediated gene silencing.
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CHAPTER 2 
PROTEIN ARGININE DEIMINASES AND ASSOCIATED CITRULLINATION: 
PHYSIOLOGICAL FUNCTIONS AND DISEASES ASSOCIATED WITH 
DYSREGULATION 
ABSTRACT: Human proteins are subjected to more than 200 known post-translational 
modifications (PTMs) (e.g., phosphorylation, glycosylation, ubiquitination, S-
nitrosylation, methylation, N-acetylation, and citrullination) and these PTMs can alter 
protein structure and function with consequent effects on the multitude of pathways 
necessary for maintaining the physiological homeostasis.  When dysregulated, however, 
the enzymes that catalyze these PTMs can impact the genesis of countless diseases.  In this 
review, we will focus on protein citrullination, a PTM catalyzed by the Protein Arginine 
Deiminase (PAD) family of enzymes.  Specifically, we will describe the roles of the PADs 
in both normal human physiology and disease.  The development of PAD inhibitors and 
their efficacy in a variety of autoimmune disorders and cancer will also be discussed.  
 
                                                          
* Erin E. Witalison, Paul R. Thompson, and Lorne J. Hofseth.  Current Drug Targets. 2015; 
16(7); 700-710.  Reprinted with permission. 
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2.1 INTRODUCTION 
 Posttranslational modifications (PTMs) can have consequential effects on protein 
structure and function.  One such PTM, citrullination, is catalyzed by the Protein Arginine 
Deiminase (PAD) family of enzymes (1).  This enzyme family consists of 5 isozymes 
(PAD1-4 and 6) (2-4) that have individual tissue specificity and target substrates.  PADs 
rely on increased concentrations of calcium to citrullinate peptidyl-arginine (5).  Under 
physiological conditions in cells, PADs are not normally active until stimulated with 
calcium.  Once stimulated, these enzymes citrullinate a number of structural proteins (e.g., 
vimentin, filaggrin, and keratin) (6, 7) and proteins involved in the regulation of gene 
transcription (e.g., histones H1, H2A, H3 and H4) (8-10).  Since PADs play functional 
roles in key cellular processes, their regulation is necessary.  There have been several 
inhibitory compounds developed to study PAD activity.  From the parent structures of Cl-
amidine and F-amidine, second generation compounds have been synthesized with 
increased isozyme specificity, in vivo stability, and bioactivity (11-13).  To date, Cl-
amidine is the most widely used pan-PAD inhibitor, while Cl4-amidine and F4-amidine 
are the most potent PAD3 specific inhibitors (13).  Many of these compounds are being 
tested as therapies and preventatives for numerous diseases where PADs are known to 
become dysregulated such as diseases of the nervous system, skin, joints, immune system, 
and colon (14-17).  Overall, based on PADs’ role in physiological and pathological 
functions (such as gene regulation and immune response), the field of PAD regulation is 
gaining traction as a promising target for the treatment and prevention of autoimmune and 
inflammatory diseases linked to abnormal PAD activity. 
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2.2 THE PROTEIN ARGININE DEIMINASE FAMILY OF ENZYMES 
2.2.1 CITRULLINATION 
 First described in 1958 by Rogers and Simmonds (1), protein citrullination is the 
process of converting peptidyl-arginine to peptidyl-citrulline.  Since citrulline is a non-
genetically encoded amino acid, citrullination occurs post-translationally (18), and because 
it is a hydrolytic reaction, it results in a 1Da decrease in mass (19, 20). As a result, the 
strongly basic positively charged side chain of arginine is hydrolyzed by water to form the 
neutral urea (Figure 2.1).  This shift in charge can affect protein-protein interactions, 
hydrogen bond formation, protein structure, and, in some cases, cause denaturation (13, 
21).  There is a wide range of cytoplasmic, nucleic, membrane, and mitochondrial proteins 
that can be citrullinated (22).  This review will discuss physiologically targeted protein 
substrates and citrullination in diseases. 
2.2.2 PADS 
 The PADs were first described in 1977 as the enzymes responsible for this PTM 
(23) and it is now known that these enzymes are cysteine hydrolases.  Citrullination 
proceeds via nucleophilic attack of a critical active site cysteine on the substrate 
guanidinium, resulting in the formation of a tetrahedral intermediate that ultimately 
collapses to form an acyl-enzyme intermediate that is subsequently hydrolyzed to form 
citrulline (Figure 2.1) (13, 19, 24).  While the substrate scope of the PADs remains poorly 
defined, it is known that these enzymes will not citrullinate free arginines or even 
methylated arginine in the context of a peptide or protein (18, 19, 25, 26).   
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2.2.3 PAD DISTRIBUTION AND STRUCTURE 
 There are 5 PAD isozymes found in humans: PAD1, PAD2, PAD3, PAD4, and 
PAD6 (2-4).  Of these isozymes, PAD6 is the only PAD for which no in vitro activity has 
been detected (27).  The PAD isozymes have unique tissue localization and overlapping 
substrates.  PADs 1 and 3 are both distributed in the epidermis and hair follicles (28), with 
PAD1 also localizing in the uterus (2, 29).  PADs 2 and 4 have widespread protein 
distributions.  For instance, PAD2 can be located in the central nervous system (CNS), 
spleen, skeletal muscle, and leukocytes (30-33).  PAD4 is found in inflammatory cells 
(macrophages and neutrophils), mammary gland cells, and tumors (16, 34, 35).  PAD6 is 
localized to eggs, ovary, and the early embryo (4, 35, 36). 
 Since the crystal structure for PAD4 has been determined, more is known about 
this isozyme.  All mammalian PAD isozymes share 70-95% homology in their amino acid 
sequence and are approximately 663 amino acids long with a molecular weight of ~74 kDa 
(Figure 2.2) (18, 24, 37, 38).  The PADs have two immunoglobulin-like subdomains at the 
N-terminus (aa 1-300) and a highly conserved C-terminal domain (aa 301-663) that 
includes the active site of the enzyme (24).  PAD4 also contains a canonical nuclear 
localization signal (NLS) (aa 56-63) within N-terminal subdomain 1 (Figure 2.2) and is at 
least partially localized to the nucleus where it deiminates histones H3 and H4 (24, 35).  
Despite lacking a canonical NLS sequence, PAD2 was also recently shown to localize to 
the nucleus and citrullinate histone H3 (39). 
2.2.4 CALCIUM DEPENDENCY 
 The PADs are calcium-dependent enzymes (5).  There are five calcium binding 
sites in PAD4, with 2 being located in the C-terminal domain of the enzyme (24) and the 
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remaining three being present in N-terminal subdomain 2.  In the absence of calcium, the 
active site has a rather open concave structure with a highly acidic region with Cys645, the 
active site nucleophile, being pointed away from the active site (24, 40).  Upon binding 
calcium, the protein undergoes a series of conformational changes that ultimately results 
in the movement of key active site residues, including Cys645, into positions that are 
competent for catalysis (24, 38).  Although the pH optimum for PAD activity is 7.6, 
calcium activation of PAD4 is pH-independent between a pH of 6.0 and 8.5 (25). 
2.2.5 PAD SUBSTRATE TARGETS 
 Not all arginine residues in a protein are equally likely to be citrullinated by PADs.  
A study investigating the citrullination of filaggrin and trichohyalin, known PAD 
substrates, was able to determine that approximately 95% and 60% of arginines were 
converted to citrulline within 3 hours of adding PAD to filaggrin (1:1000 ratio) or 
trichohyalin (1:30 ratio) substrates, respectively (21).  These results demonstrated that the 
secondary structure of a protein has an effect on the occurrence of citrullination.  Filaggrin, 
which has a secondary structure consisting mainly of a ß-turn, is citrullinated more 
frequently (~95%) than trichohyalin (60%), which is composed of a single α-helix (19, 21).  
Likewise, Tarcsa et al. (1996) determined the amino acid sequences for filaggrin and 
trichohyalin and quantified the occurrence of each arginine residue being citrullinated 
found in each substrate (21).  For example, it was found that arginines located next to 
aspartic acid residues were citrullinated about 80-90% of the time, while arginines found 
next to glutamic acid residues were rarely citrullinated (0-5%) (19, 21).  Furthermore, 
arginine residues that are located next to an amino group or are flanked by proline are 
poorly citrullinated (19, 41). 
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 Therefore, depending on the importance, location, structure, and abundance of the 
arginine residues in a protein, citrullination can have variable effects, such as changes in 
protein-protein interactions or denaturation (13, 21).  PAD1 targets keratin and filaggrin 
(7); PAD2 targets myelin basic protein (MBP) (30), vimentin (42), actin, and histones (39); 
PAD 3 targets filaggrin, trichohyalin (7), apoptosis-inducing factor (AIF), and vimentin 
(43); PAD4 targets multiple proteins involved in gene regulation (histones (24, 44), 
inhibitor of growth 4 (ING4) (45), p300 (46), p21 (47)) and apoptosis (nucleophosmin (48), 
nuclear lamin C (49)) ; and there are no known protein substrates of PAD6 (Table 2.1) 
(35).  Several of these protein targets of PAD citrullination will be described throughout 
the next sections that have a high arginine content (~10%) and/or have particular arginine-
rich regions that are critical for their structure and function. 
2.3 NORMAL PAD FUNCTION 
2.3.1 NORMAL CELLULAR PROCESSES INVOLVING PADS 
 Under physiological conditions, PADs are usually inactive because calcium 
concentration is maintained at very low levels in the cell (10-8 to 10-6 M) (19, 50).  Normal 
functioning PADs become activated during certain events, such as apoptosis and terminal 
epidermal differentiation, where calcium levels are above the physiological concentration 
(19, 51).  Intriguingly, PADs function in gene regulation and other processes at 
physiological concentrations of calcium; therefore mechanisms to modulate the calcium-
dependence of the enzymes must exist (19).  In this section, we will discuss four key 
cellular processes in which protein citrullination is known to play a role. 
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2.3.2 APOPTOSIS 
 Calcium acts as a signaling molecule to coordinate apoptosis; therefore, it is needed 
at high concentrations within apoptotic cells (52).  PADs are also activated by these higher 
concentrations of calcium in cells undergoing apoptosis.  However, once activated, it is not 
fully understood how PADs determine their substrate specificity.  One consideration is that 
PADs may target proteins that are arginine-rich or have arginine-rich regions within their 
amino acid sequence.  In support of this idea, vimentin, an intermediate filament, is found 
to be citrullinated during apoptosis (51) and Inagaki et al. (1989) report that PADs 
citrullinate the non-α-helical head domain of the vimentin protein (6).  The vimentin 
protein is 466aa long with 9.2% arginine residues (53).  In this non-α-helical head domain 
(aa 2-95), there are 12 arginines that are citrullinated by the PADs (53).  When vimentin is 
citrullinated, the polymer disassembles and the monomers cannot rejoin properly to form 
the structural support and organelle anchor, triggering structural collapse and further 
completion of apoptosis (6, 19, 54).  For instance, PAD2 can induce apoptosis by 
citrullinating vimentin, specifically in macrophages.  Overexpression of PAD2 leads to 
vimentin citrullination and apoptosis in Jurkat cells (42).     
 Likewise, histones and nucleophosmin are known targets of PAD4 and their 
citrullination can cause the nucleosome and nuclear lamina to collapse, also initiating 
apoptosis (18, 19).  The oligomerization of nucleophosmin is required for localization to 
the nucleolus and will prevent apoptosis by inhibiting p53 localization to the mitochondria 
(a key step in apoptosis) (55, 56).   Therefore, improper folding/binding caused by 
citrullination of nucleophosmin can induce apoptosis associated with p53 localization to 
the mitochondria.  Also reported, PAD4 overexpression upregulates p53 and stimulates 
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mitochondrial-associated apoptosis (57).  Additionally, Mizoguchi et al. (1998) reported 
the citrullination of a 70kDa nuclear protein localized on the periphery of the nucleus was 
linked to dissociation of the nuclear lamina during apoptosis (58).  Recently, PAD3 was 
found to be necessary for apoptosis-inducing factor (AIF)-mediated apoptosis (43).  
Overall, PAD activation (due to amplified calcium levels during the early stages of 
apoptosis) can facilitate apoptotic cell death by citrullinating several nuclear and 
cytoskeletal proteins that can cause structural changes resulting in the disintegration of 
secondary and tertiary protein structures (6, 18, 19). 
2.3.3 STRUCTURAL SUPPORT 
 Additionally, PADs are involved in the organization of structural proteins in cells 
undergoing terminal epidermal differentiation (19, 59).  This differentiation is mediated by 
calcium, so there are usually higher concentrations of calcium, which in turn activates the 
PADs.  Within the epidermis, PADs can citrullinate structural proteins, such as, keratin, 
filaggrin, and vimentin.  Filaggrin, as an example, is 4061aa long with a relatively high 
arginine content (10.8%) (53).  Upon calcium-mediated terminal differentiation of 
epidermal cells, activated PADs can citrullinate these proteins, causing partial unfolding, 
which makes these proteins more susceptible to protease degradation (19, 60). 
2.3.4 GENE REGULATION 
 In cells not undergoing apoptosis, PADs can regulate gene expression (10, 35, 44-
47, 61-63).  Most research on PAD involvement in gene regulation has been performed on 
PAD4.  One of the best studied systems is the PAD4-mediated regulation of the p53 
pathway.  For instance, PAD4 citrullinates ING4 protein (45) and once modified, this 
protein does not bind to p53 and is more prone to protease degradation.  Without the 
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interaction of ING4, the transcriptional targets (e.g. p21) of p53 are suppressed (Figure 
2.3A) (45).  Another mechanism involves the citrullination of methylated arginine on 
histones.  In this mechanism, PAD4 is recruited to gene promoters where it mediates the 
citrullination of histone H4 at R3 and histone H3 at R2, R8, and R17 and the modification 
is associated with gene repression (44).  As an example, PAD4, which interacts with the 
regulatory domain of p53, targets p21 at the p53-binding sites on the promoter region (47).  
This interaction causes citrullination of histones on the p21 promoter region, ultimately 
repressing p21 transcription since p53 cannot properly bind to the p21 promoter region 
(Figure 2.3B) (47).  This impaired binding is due to the changes in charge that can affect 
protein-protein interactions and hydrogen bond formation.  Also, citrullination of the 
histones in the p53-binding sites on the promoter region may cause conformational changes 
that sterically hinder p53 binding.  Li et al. (2010) correspondingly reported that PAD4 
citrullinated histones on p53 target gene promoters, but they further found that PAD4 relied 
on the histone deacetylase, HDAC2, to repress the gene expression of p53 targets (Figure 
2.3B) (61).  It is still unknown how PAD4 is recruited to specific promoters or even how 
they are activated at physiological calcium levels (35, 62, 63).  Wang & Wang (2013) 
propose a mechanism where PAD4 binds to the promoter region of p53 and represses target 
gene expression by histone citrullination during periods where the damage response 
pathways are not needed.  Then, when these pathways are needed (i.e. in response to DNA 
damage), PAD4 dissociates from the promoter and the target genes are activated once again 
(35).  There is also evidence that PAD4 can act as a transcriptional coactivator.  In this 
process, PAD4 citrullinates the Arg2142 in the GRIP1 binding domain of the 
transcriptional coactivator p300.  Once p300 is citrullinated, the interaction between it and 
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GRIP1, another coactivator, is enhanced (Figure 2.3C) (46).  Perhaps, in this case, the 
neutral charge of citrulline could be more complementary for the interaction between 
GRIP1 and p300.  How the PADs get activated to modulate gene transcription is not 
known, but György et al. (2006) hypothesized that PADs may be active with strict substrate 
specificity at low levels of calcium and this could explain PAD involvement in gene 
regulation (19).  However, this is unlikely to be correct because different substrates have 
similar calcium dependencies (62).   
 PAD4 also plays a role in pluripotency as a transcriptional regulator of several key 
genes.  PAD4 upregulates pluripotent markers (e.g. Klf2, Tcl1, Tcfap2c, Kit, Nanog) and 
downregulates differentiation markers (e.g. Prickle1, Epha1, Wnt8a) (8, 64).  In fact, 
citrullination of histones H1 and H3, by PAD4, regulates the induction of pluripotency and 
reprograming of stem cells during early embryonic development (8, 64).  Slade et al. (2014) 
also suggest that other PAD isozymes (PAD1-3) may impact pluripotency at other stages 
of differentiation since they showed individual expression in embryonic stem cells and 
induced pluripotent cells (8, 64). 
2.3.5 IMMUNE RESPONSE 
 PADs 2 and 4 are involved in inflammatory immune responses.   PAD4 is mainly 
expressed in macrophages, neutrophils, and eosinophils whereas PAD2 is highly expressed 
in macrophages (16).  In macrophages, PAD2 becomes activated due to increased levels of 
calcium (65).  Also, PAD4 is involved in the citrullination of histones in neutrophils.  After 
activated PAD4 has translocated to the nucleus of neutrophils, hypercitrullination of 
histones can trigger the production of neutrophil extracellular traps (NETs) that trap 
bacteria and other pathogens.  The release of NETs can provoke an autoimmune response 
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to NET-associated nuclear antigens and granule proteins, leading to a pro-inflammatory 
form of programed cell death termed ‘NET-osis’ (40, 66, 67). 
2.4 PAD INHIBITORS 
2.4.1 DEVELOPMENT OF F-AMIDINE, THE FIRST BIOACTIVE PAD INHIBITOR 
 Thompson and colleagues reported the first bioactive PAD inhibitor in 2006 when 
they described the synthesis and characterization of F-amidine.  The structure of F-amidine 
is based on benzoyl-arginine amide (BAA), one of the best small molecule substrates 
identified for the PADs (25, 68).  Since the PADs preferentially hydrolyze a positively 
charged guanidinium, Thompson hypothesized that replacement of one of the amino 
groups with a methylene fluoride would generate a compound that could covalently modify 
the enzyme (Figure 2.4A) (68).  The resulting fluoroacetamidine containing compound 
maintains the positive charge and most of the hydrogen bonding capabilities of the 
substrate guanidinium, but due to the electron withdrawing nature of the fluorine can 
undergo reaction with a cysteine residue present in the active site of the enzyme (68).  This 
compound, F-amidine, inhibits PAD4 with a kinact/KI value of 3000 M
-1s-1 and was the most 
potent pan-PAD inhibitor at the time.  Further experiments demonstrated that F-amidine 
irreversibly inhibits PAD4 by modifying Cys645, the active site cysteine (69).  F-amidine 
is bioavailable and has been used to confirm that PAD activity can inhibit gene expression 
(68). 
2.4.2 CL-AMIDINE 
 Building on the success of F-amidine, Thompson and colleagues next synthesized 
a series of compounds in which they optimized the identity of the warhead by replacing 
the fluorine with either a chlorine or hydrogen.  They also optimized the side chain length 
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by synthesizing compounds in which the side chain is varied between two and four 
methylene units (69).  From these compounds, Cl-amidine was found to be the most potent 
compound with a kinact/KI value of 13000 M
-1s-1 for PAD4 (69).  Subsequent work showed 
that it inhibits all four active PAD isozymes with similar potencies (11).  Cl-amidine is 
structurally identical to F-amidine except that it has chlorine substituted for the fluorine in 
the haloacetamidine warhead (Figure 2.4B) (11, 69).  By contrast, compounds that lacked 
an electron withdrawing group or had shorter or longer side chains were rather poor PAD 
inhibitors (69). 
 Cl-amidine, like F-amidine, preferentially inhibits the activated, calcium-bound 
form of the PADs (69) and based on detailed mechanistic studies (13) both compounds 
irreversibly inhibit the enzyme via nucleophilic attack on the amidine carbon, which results 
in the formation of a tetrahedral intermediate that is stabilized by proton donation from 
His471, the general base in the normal PAD-catalyzed reaction.  The sulfur then attacks 
the halide bearing carbon to form a three member sulfonium ring.  Proton abstraction and 
collapse of the tetrahedral intermediate cleaves the sulfonium ring to form the stable 
thioether adduct (40). 
 Since its development, Cl-amidine has been the most widely used PAD inhibitor 
and studies indicate that it is bioavailable and can inhibit PAD4 activity found in the 
nucleus (69).  Remarkably, Cl-amidine was cytotoxic to cancer cell lines (MCF-7, HL-60, 
and HT29) and showed minimal cytotoxic effects on noncancerous cell lines (NIH 3T3 and 
HL-60 granulocytes) (70).   Furthermore, Cl-amidine triggered the differentiation of the 
leukemic HL-60 cell line into HL-60 granulocytes (70).  As will be discussed later on in 
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this review, Cl-amidine has been tested on numerous disease models and shows promise 
for the treatment and/or prevention of many diseases. 
2.4.3 OTHER PAD4 INHIBITORS 
 In order to detect other PAD4 inhibitors, a competitive screening assay was 
developed using Rhodamine-conjugated F-amidine.  This assay overcomes the challenges 
of traditional PAD activity assays because it does not require strong acids, high 
temperatures, and toxic reagents that are normally necessary to detect the citrulline product 
of the reaction (71).  Using this assay, multiple drugs that are typically used to treat RA 
were evaluated for their ability to inhibit PAD4.  Streptomycin was found to be a 
competitive inhibitor whereas minocycline and chlorotetracycline were found to be mixed 
inhibitors that did not bind to the active site (71).  These drugs can potentially provide 
scaffolds for the next generation of PAD inhibitors (71, 72). 
2.4.4 PAD SPECIFIC INHIBITORS 
 In disease, it has been shown that only certain PADs may be dysregulated (e.g. 
PAD4 in RA); therefore, the development of PAD specific inhibitors has been explored.  
Structure activity relationships (SAR) were generated for F-amidine and Cl-amidine to 
identify modifications that would increase interisozyme selectivity.  One outcome of these 
efforts was the identification of o-F-amidine and o-Cl-amidine, which contain an ortho-
carboxylate on the benzoyl ring of the parent structures (11).  Both compounds are 
significantly more potent than the parent compounds and also exhibited PAD specificity.  
For example, o-F-amidine selectively inhibits PAD1, whereas o-Cl-amidine preferentially 
inhibits PADs 1 and 4 (11).  Additional studies identified D-o-F-amidine and D-Cl-amidine 
as a pair of PAD1 specific compounds that possess increased in vivo stability (12).  As of 
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2010, Cl4-amidine and F4-amidine, which were tested previously on PAD4, are the 
strongest PAD3 specific inhibitors (13).  TDFA, a tripeptide composed of threonine, 
aspartate and F-amidine is the most potent PAD4 specific inhibitor to be reported (73).  
Additionally, in 2005, Kearney et al. showed that different metals inhibit PAD activity.  In 
their studies, they found that manganese, samarium, and zinc did not allow the PADs to 
structurally change into the catalytically active form in the presence of calcium (25).  These 
findings are another step in the development of new and more specific PAD inhibitors. 
2.5 PAD DYSREGULATION IN DISEASES 
2.5.1 DISEASES ASSOCIATED WITH PAD DYSREGULATION 
 PADs have a role in maintaining many vital cellular processes; therefore, it is 
necessary for a balance in PAD activity or these processes can become uncontrollable with 
potentially deleterious side effects.  Due to this delicate balance, it is not hard to believe 
that there are numerous diseases associated with PAD dysregulation and abnormal levels 
of citrullination.  In this section, we will discuss our current understanding of the role that 
PADs play in these diseases even though much (i.e. specific cause for dysregulation) is still 
to be discerned.  We will also discuss specific PAD isozymes that are associated with 
certain types of diseases, such as PAD1 is linked to psoriasis (15) and PADs 2 and 4 are 
heavily involved with neurodegenerative and inflammatory (16, 17) diseases and cancers 
(34). 
2.5.2 CAUSES OF PAD DYSREGULATION 
 Not much is known about what causes PADs to become dysregulated, but there are 
several proposed scenarios that may lead to abnormal levels of citrullinated proteins.  For 
example, (i) PAD activity may become uncontrolled at extreme levels of calcium and may 
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lose target specificity (19).  The lack of target specificity could cause loss of activity and 
even total denaturation in arginine-rich proteins.  As well, (ii) increased translation of 
PADs could also explain for increased levels of citrullination; however, it is unknown what 
might cause the increased translation (19, 74).  (iii) There is abnormal TNFα signaling in 
Rheumatoid Arthritis (RA) and Ulcerative Colitis (UC), TNFα can induce PAD4 
translocation (75), and PADs can citrullinate TNFα (76).  Taken altogether, perhaps RA 
and UC result, in part, from PAD dysregulation (17).  Finally, (iv) PAD4 has been seen to 
autocitrullinate and this may be a form of self-regulation.  Although autocitrullination is 
not shown to interfere with specificity or activity levels of the enzyme, it does affect the 
enzyme’s interaction with other proteins involved in the PTM of histones (62).  Once again, 
as discussed in Section 2.5, the amino acid sequence and structure surrounding arginine 
residues can also influence susceptibility to citrullination (19, 21). 
2.5.3 PADS IN THE CNS 
2.5.3.1 NORMAL FUNCTION 
 PAD2 is the predominant isozyme found in the nervous system (14, 30, 35). While 
PAD4 does not normally target CNS substrates, it has been discovered in the cytoplasmic 
granules of neuronal cells (77).  PAD2 and 4 are normally in the inactive state in the adult 
CNS (14), but are active during development (78). 
2.5.3.2 ALZHEIMER’S DISEASE 
 PAD 2 and 4 become activated in the CNS during neurodegenerative processes 
(14).   Alzheimer’s disease is linked to an increase in abnormal accumulation of misfolded 
proteins in the hippocampal region of the brain.  Interestingly, an increased amount of 
PAD2 and citrullinated proteins are found in the hippocampus of patients suffering from 
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Alzheimer’s (14).  The structural proteins vimentin and glial fibrillary acidic protein 
(GFAP) are some of the proteins found to be citrullinated in the hippocampus (19, 38, 79, 
80).  Likewise, PAD4 and citrullinated proteins were colocalized in regions of 
neurodegeneration and inflammation in Alzheimer’s patients (77). 
2.5.3.3 PRION DISEASE 
 Similar to Alzheimer’s disease, prion diseases involve misfolded proteins alongside 
deterioration of many structures in the brain (79).  Calcium levels are dysregulated in these 
diseases and are likely the reason for high amounts of active PADs and citrullinated 
proteins in the CNS (79). 
2.5.3.4 MULTIPLE SCLEROSIS 
 In the CNS, the MBP is essential for maintaining the myelin sheath, which is 
involved in neuronal signal transduction throughout the CNS (19, 79).  Signal transduction 
requires the myelin sheath to act as an insulator with the MBP holding a positive charge 
(18).  In Multiple Sclerosis (MS), the myelin sheath is degraded, leading to decreased 
signaling.  PAD isozymes 2 and 4 are involved in the pathology of MS (19, 30, 35, 38, 75).  
It is thought that PAD4 is brought to the CNS by infiltrating macrophages during diseased 
states and may citrullinate proteins that are not naturally targeted in the CNS (81).  The 
excessive citrullination of the MBP is thought to be a major contributor to the disease (19, 
30, 38, 82).  It has been established that up to 90% of MBPs are citrullinated in severe 
forms of the disease (38, 83).  Citrullination causes MBP to partially unfold and make them 
more susceptible to degradation by proteases, like cathepsin D (19, 83, 84).  Also the 
change from positively charged arginine to neutral citrulline is not optimal for the electrical 
specifications required for proper signal transduction (19, 84).  The high frequency of 
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arginine residues (10.3%) in the amino acid sequence of MBP may also explain why it is 
targeted by PADs (85).  While the PAD2 knockout still develops experimental autoimmune 
encephalomyelitis (EAE), a preclinical animal model of MS, overexpression of PAD2 
gives MS-like symptoms, suggesting that multiple PAD isozymes are involved in the 
etiology of this disease (86). 
2.5.4 PADS IN THE EPIDERMIS 
2.5.4.1 NORMAL FUNCTION 
 PAD1 is highly expressed in the epidermis where it citrullinates keratin K1and 
filaggrin (7, 19, 35, 38).  These proteins aid in the maintenance of homeostasis and 
structural flexibility in the dermis and epidermis (7, 18, 38).  In normal skin, keratin K1 is 
citrullinated at low levels and degraded to prevent cornification. 
2.5.4.2 PSORIASIS 
 Psoriasis is a type of dermatitis characterized by excessive proliferation and 
atypical epidermal differentiation which contribute to the flaky, dry patches of skin (19, 
38).  The possible cause of the disease can be explained due to the fact that there is no 
citrullinated keratin K1 found in skin samples from patients with psoriasis (15, 18, 19, 38).  
The lack of citrullinated proteins causes excessive cornification and an inflammatory 
response (15, 18, 19, 35, 38).  Psoriasis is the only disease linked to PAD1 dysregulation 
and it is unknown what triggers its decreased enzymatic activity (15, 18, 35, 38). 
2.5.5 PADS IN THE SYNOVIAL JOINTS 
2.5.5.1 NORMAL FUNCTION 
 PAD2 and PAD4 mRNA and protein are expressed in peripheral blood from both 
RA patients and healthy control patients (16).  In healthy patients as compared to the RA 
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patients, the PAD isozymes were inactive since the monocytes and macrophages, where 
the PADs were located, were not involved in an inflammatory response (16).  Also, there 
were fewer macrophages and monocytes found in the joints in healthy patients.  These 
PAD enzymes are typically dormant in the leukocytes and synovial joints until they are 
activated during an inflammatory immune response. 
2.5.5.2 RHEUMATOID ARTHRITIS 
 RA is a chronic inflammatory disease of the joints that is thought to be caused or 
intensified by PAD dysregulation.  In patients with RA, an increase in PAD2 and 4 
translation is observed alongside increased enzyme presence and activation (19, 74).  
Vossenaar et al. (2004) developed a model for PAD infiltration into the synovial joints of 
RA patients where PAD2 and PAD4 are expressed in monocytes and macrophages that are 
recruited to the joint (16).  Their proposed model shows that the activated macrophages 
and monocytes, containing the inactive PADs, are eventually degraded in the joints and 
undergo apoptosis where the PAD isozymes become activated as calcium levels rise.  PAD 
activation then causes cellular protein (e.g. vimentin) citrullination and the PADs can seep 
out of the cell to target extracellular proteins (16).  For example, PAD2 and 4 can 
citrullinate fibrin in the affected joints, producing an immune response.  Also, PAD4 has 
been shown to citrullinate antithrombin, a thrombin inhibitor.  Thrombin is involved with 
the onset of RA; therefore, the citrullination of antithrombin may further lead to RA (87).   
 In many inflammatory diseases, such as RA, inflammation is a result of an atypical 
immune response to bacteria and other stresses (e.g. citrullination) (19, 88).  NETs are 
found to be dysregulated in RA, causing an increase in antibodies against citrullinated 
proteins (89).  Correspondingly, there are high levels of antibodies against citrullinated 
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proteins found in the blood of RA patients, possibly explaining the atypical immune and 
inflammatory responses correlated with RA (18, 89).  Importantly, the presence of these 
antibodies is the most specific diagnostic for the disease and they are present in the sera of 
RA patients 4-5 years, on average, before clinical symptoms appear (90).  This suggests 
that dysregulated PAD activity is potentially disease initiating.  Despite the specific causes 
of RA still being unknown, there have been several haplotypes of PAD4 that are correlated 
with an increased risk of developing the disease (91). 
2.5.6 PADS AND THEIR ROLE IN NET FORMATION 
 As mentioned in Section 3.5, PAD4 is involved in a unique form of cell death, 
‘NETosis’.  Released NETs actively trap bacteria and other pathogens that prompt this type 
of immune response.  This immune response is a common defense mechanism against 
foreign microbes.  The effects of NET dysregulation play a role in a number of other 
autoimmune diseases, including psoriasis (92), systemic lupus erythematosus (SLE) (93), 
and RA as previously discussed.  Interestingly, pro-inflammatory IL-17 is released during 
NET formation in psoriasis, SLE, and RA, indicating that this aberrant immune response 
triggers an inflammatory response (89, 92, 94). 
2.5.7 PADS IN THE COLON 
2.5.7.1 NORMAL FUNCTION 
 There is no data on the normal function of PADs in the human colon.  Perhaps the 
presence and dormancy of PADs in normal colonic tissue resembles that in the healthy, 
non-arthritic patients, as described in Vossenaar et al. (2004), where the inactive PADs are 
present in macrophages and monocytes (16). 
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2.5.7.2 ULCERATIVE COLITIS 
 UC is another inflammatory disease where PADs 2 and 4 are involved in the 
pathogenesis of the disease.  UC is characterized by chronic, relapsing periods of 
inflammation in the colon.  The exact cause of the disease is unknown but it has been 
proposed that an atypical immune response is triggered by an inflammatory response to 
several cytokines produced by activated macrophages (88).  In UC, similar to RA, high 
levels of anti-citrullinated protein antibodies are found in the blood (17).  Thus, UC could 
be caused by an autoimmune response to improperly folded proteins caused by excessive 
citrullination.  The specific PAD4 haplotypes that have been linked to genetic susceptibility 
of RA have similarly been linked to UC (91). 
2.5.8 PADS IN CANCER 
 PAD dysregulation is also associated with cancer (34).  For example, PAD2 levels 
are elevated in luminal breast cancer cell lines (95).  Likewise, since PAD4 regulates gene 
expression as a corepressor, its dysregulation is thought to be linked to various cancers, 
such as breast, renal, and colorectal cancer (34, 47).  Chang et al. (2009) found that PAD4 
protein and mRNA expression levels were significantly increased in more than 12 types of 
cancers, including breast, lung, liver, esophageal, colorectal, renal, bladder, and ovarian 
malignant tumors collected from patients (34).  There were elevated levels of PAD4 found 
in these cancerous tissues, similar to the increased PAD4 levels in the tissues of patients 
suffering from inflammatory diseases (i.e. RA, UC) (34, 96).  Interestingly, in benign 
tumors and non-cancerous inflamed tissue samples, PAD4 was not expressed, except tissue 
samples from the gastrointestinal tract (34).  These higher PAD levels in tumor versus non-
tumor tissues suggest that abnormal PAD activity/citrullination can cause a dysregulation 
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of gene expression.  When tumor suppressor genes are the targets of PAD4 dysregulation, 
tumorigenesis can occur.  In contrast to results indicating that PAD4 overexpression 
upregulates p53-mediated apoptosis, PAD4 has been shown to promote tumorigenesis by 
suppressing p53 and disrupting the cell cycle and apoptosis (57).  Similarly, PAD4 
citrullination of the intermediate filament, cytokeratin, is determined to interrupt apoptosis 
(57).  Overall, these findings support the premise that PADs promote tumorigenesis.   
 Alternatively, Stadler et al. (2013) reported that PAD4 negatively regulates tumor 
invasiveness in breast cancer models in vitro and in vivo (97).  In this study, PAD4 
citrullinated glycogen synthase kinase-3ß (GSK3ß) in MCF-7 breast cancer cells and in a 
tumor xenograft animal model.  Upon PAD4 downregulation, there was an increase in 
epithelial-to-mesenchymal transition (EMT) and tumor invasiveness (97).  These results 
indicate a complex role of PAD4 in tumorigenesis with contradicting roles between various 
cancer types. 
2.5.9 PAD INHIBITORS USED IN DISEASES 
 In addition to using PAD inhibitors to study PAD biology, many labs that work on 
models of diseases caused by PAD dysregulation are testing the potency and safety of these 
inhibitors to treat and prevent their disease of interest.  For example, 2-chloroacetamidine 
was found to reverse the effects of PAD activity in numerous mouse models of MS (98).  
Likewise, current inhibitors that show efficacy against PAD2 and especially PAD4 have 
been tested on models of RA.  Excitingly, Cl-amidine, a pan-PAD inhibitor, was found to 
reduce clinical symptoms and disease severity in an in vivo mouse model of RA (99).  
 The progress made in using PAD inhibitors for the treatment of RA should be 
translatable to other hyperactive immune and inflammatory diseases associated with PAD 
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dysregulation.  As evidence of translation to other diseases, Cl-amidine was found to 
prevent and treat UC when given in a mouse model of UC (17).  Additionally, Cui et al. 
(2013) reported that Cl-amidine induced the upregulation of several tumor suppressor 
microRNAs, in HCT116 colon cancer cell line, that are reportedly downregulated in 
cancers (e.g. miR-16, let-7) (100-103).  Cl-amidine also shows proven efficacy in a 
multitude of other disease models including: cancer (70, 100, 104), SLE (105), a spinal 
cord injury model (106), atherosclerosis (107), and hypoxia (108).  Altogether, these 
findings demonstrate the potential for PAD inhibitors as disease treatments and 
preventatives. 
2.6 CONCLUSION 
 As discussed in this review, the Protein Arginine Deiminases catalyze the 
citrullination of protein embedded arginine residues, a PTM that has many functional 
implications on target proteins.  Citrullination by PADs affects vital cellular responses 
involving cell death (via apoptosis and NET-osis), terminal epidermal cell differentiation, 
and gene regulation.  PADs have complex roles in these processes and the particular 
regulatory mechanisms that control PAD activation/inactivation need to be explored.  To 
better understand the mechanisms and physiological functions of PADs, a series of potent 
pan-PAD and isozyme-specific inhibitors have been used.  Likewise, these PAD inhibitors 
have been tested on in vitro and in vivo disease models that are associated with aberrant 
PAD regulation.  Many of these studies have seen success in treatment and/or prevention 
of diseases including: rheumatoid arthritis, multiple sclerosis, ulcerative colitis, and cancer.  
Future research on typical PAD activity and atypical involvement in disease will certainly 
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continue to expand as more encouraging results spotlighting effective PAD regulation are 
published. 
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Table 2.1. PAD target substrates. Known substrates that are targeted by the individual 
isozymes of the PAD family of isozymes. 
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FIGURES 
 
 
 
Figure 2.1. The process of citrullination. The primary amine group of peptidyl-arginine 
is hydrolyzed upon interaction with the cysteine of the deiminating enzyme and is replaced 
to form a keto group. The end products of this reaction are peptidyl-citrulline and free 
ammonium. 
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Figure 2.2. Human PAD isozyme sequence alignments. Amino acid sequence alignment of the PAD isozymes with approximately aa 
1-300 and 301-663 containing the N-terminus and C-terminus domains, respectively. Highlighted in black are amino acids that are 
conserved in all 5 isozymes, while gray highlighted amino acids are conserved in 4 of the 5 isozymes. In PADs 1-4, the important 
cysteine residue (Cys645) in the active site is highlighted in green and, in PAD4, the nuclear localization signal (NLS) sequence is 
highlighted in blue.
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Figure 2.3. Mechanisms of gene regulation involving PADs. A) Activated PAD4 
citrullinates ING4 at the nuclear localization signal (NLS) region. Therefore, the regulatory 
domain (RD) of p53 cannot bind to the NLS of ING4, leading to inhibition of p53 
acetylation and inhibition of subsequent upregulation of p21. B) PAD4 interacts with the 
regulatory domain of p53. The PAD4 attached to p53 is recruited to the promoter region 
(PR) of p21 where PAD4 citrullinates methylated arginine on histones at the promoter 
region. This citrullination, along with HDAC2, inhibits p21 transcription, resulting in an 
increase in cell proliferation and inhibition of cell cycle arrest. C) PAD4 citrullinates 
methylated arginine on the GRIP1 binding domain (BD) of p300. This leads to increased 
binding to GRIP1 and results in increased ER-mediated transcription. 
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Figure 2.4. Structures of PAD inhibitors F-amidine and Cl-amidine. A) F-amidine and 
B) Cl-amidine share similar structures to arginine. Also these compounds are positive H 
bond donors that can sterically fit in the active site of PADs. 
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CHAPTER 3 
INHIBITING PROTEIN ARGININE DEIMINASES HAS ANTI-OXIDANT 
CONSEQUENCES  
ABSTRACT: Ulcerative colitis is a dynamic, idiopathic, chronic inflammatory condition that 
carries a high colon cancer risk.  We previously showed that Cl-amidine, a small molecule 
inhibitor of the protein arginine deiminases (PADs), suppresses colitis in mice.  Since 
colitis is defined as inflammation of the colon associated with infiltration of white blood 
cells that release free radicals, and citrullination is an inflammation-dependent process, we 
asked whether Cl-amidine has anti-oxidant properties.  Here, we show that colitis, induced 
with azoxymethane (AOM) via intraperitoneal injection + 2% dextran sulfate sodium 
(DSS) in the drinking water, is suppressed by Cl-amidine (also given in the drinking water).  
iNOS, an inflammatory marker, was also down-regulated in macrophages by Cl-amidine.  
Since epithelial cell DNA damage associated with colitis is at least in part a result of an 
oxidative burst from overactive leukocytes, we tested the hypothesis that Cl-amidine can 
inhibit leukocyte activation, as well as subsequent target epithelial cell DNA damage in 
vitro and in vivo.  Results are consistent with this hypothesis, and since DNA damage is a 
pro-cancerous mechanism, our data predicts that Cl-amidine will not only suppress colitis, 
but we hypothesize that it may prevent colon cancer associated with colitis. 
 
                                                          
* Erin E. Witalison, Xiangli Cui, Anne B. Hofseth, Venkataraman Subramanian, Corey P. 
Causey, Paul R. Thompson, and Lorne J. Hofseth.  Journal of Pharmacology and 
Experimental Therapeutics.  2015; 353(1); 64-70.  Reprinted with permission. 
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3.1 INTRODUCTION 
Ulcerative colitis is a heterogeneous, chronic, relapsing inflammatory bowel 
disease (IBD) that has a significant impact on quality of life.  The millions of people who 
have this disease have an increased colon cancer risk.  Despite varying causes (e.g. 
environmental factors, genetic susceptibility, imbalanced enteric bacteria), the end-result 
is an abnormal immune response with repeated episodes of colonic inflammation.  While 
not everyone with colitis develops colon cancer, risk increases when disease duration 
exceeds 10 years, on the order of 0.5-1.0% annually (1). Conventional colitis treatments 
can reduce periods of active disease and help maintain remission, but these treatments often 
bring marginal results, patients become refractory, and develop serious side effects.  Hence, 
we continue to look for less toxic and more efficacious drugs to suppress colitis and prevent 
colon cancer. 
Protein Arginine Deiminases (PADs) are an enzyme family that converts peptidyl-
Arginine to peptidyl-Citrulline (ArgCit) (2), a process called ‘citrullination’.  Mammals 
encode 5 isozymes within a single evolutionarily conserved gene cluster located on human 
chromosome 1 (1p35-36) (3).  Mammalian PAD family members (PAD1-4 and 6) are 
highly related enzymes within and between individual species.  PAD-mediated 
citrullination post-translationally modifies target proteins, which affects their function (3).  
Recently, protein citrullination has received increased attention due to its role in the 
pathogenesis of various inflammatory conditions, such as rheumatoid arthritis, multiple 
sclerosis, psoriasis, chronic obstructive pulmonary disease, neurodegenerative diseases 
and, due to its emerging role in various human and animal cancers (4).  Biochemical and 
genetic evidence suggests that dysregulated PADs also contribute to the onset and 
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progression of colitis and colon cancer.  For example, increased PAD levels are observed 
in colonic inflammatory lesions in Crohn’s disease (5).  We have confirmed that PADs are 
also overexpressed in the colons of colitis patients and in mouse colitis (6).  PAD levels 
have also been reported to be increased in tumors, including colon adenocarcinomas (4, 7).  
Importantly, we showed that Cl-amidine (Figure 3.1), a novel, small molecule PAD 
inhibitor, delivered by oral gavage, suppresses mouse colitis (6).  It should be noted that 
Cl-amidine irreversibly inhibits PADs through the covalent modification of Cys645 in the 
active site of the enzymes (8); and due to steric hindrance, can only inhibit activated PADs 
that have undergone the calcium-dependent conformational change at the active site (9).  
 Because citrullination is inflammation-dependent (10), PADs cause citrullination, 
PAD inhibition by Cl-amidine suppresses inflammation, and inflammation is characterized 
by infiltrating leukocytes releasing free radicals (‘oxidative stress’) (11); it is possible that 
Cl-amidine also has anti-oxidant properties.  To better understand the mechanisms by 
which Cl-amidine suppresses colitis, and potentially protects against colitis-associated 
colon cancer, we explored the anti-oxidant consequences of PAD inhibition as well as its 
ability to protect against DNA damage in target epithelial cells in vitro and in vivo.   
3.2 MATERIALS AND METHODS 
3.2.1 CL-AMIDINE 
The synthesis of Cl-amidine has been described previously (9, 12). 
3.2.2 CELL CULTURE AND TREATMENT 
ANA-1 mouse macrophages or HCT116 human colon cancer cell lines were 
maintained in Dulbecco’s Modified Eagles Media (DMEM, Hyclone, Logan, UT) 
supplemented with 10% Fetal Bovine Serum (FBS, Biofluids, Rockville, MD), penicillin 
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(10 U/mL) and streptomycin (10 µg/mL, Biofluids, Rockville, MD).  Experiments with Cl-
amidine were carried out by pre-incubating cells with 0-10µg/mL (0-25 µM) Cl-amidine 
for 12 h.  To activate ANA-1 cells, Cl-amidine was washed off, then cells were exposed to 
100 U/mL IFN- (R&D Systems, Minneapolis, MN). 
3.2.3 CO-CULTURE CONDITIONS 
Co-culture experiments were carried out as previously described (13) with 
modifications.  HCT116 colon cancer cells were seeded at 2.5 x 106 cells per 150 mm 
culture dish 24 h before exposure to Cl-amidine (10 µg/mL) for 12 h.  Cl-amidine was 
washed off, then HCT116 cells were exposed to IFN-γ-activated or non-activated ANA-1 
cells.  ANA-1 cells were added to the actively growing colon cancer cells at a 3:1 ratio 
(ANA-1:HCT116 cells).  The co-culture was incubated for 4 h before harvest.  After 
harvest, HCT116 and ANA-1 cells were separated with MACS mini-column separators 
and CD45+ micro-beads.  HCT116 cells were examined for DNA damage by Comet 
analysis. ANA-1 cells were examined for oxidative bursts by chemiluminescence. 
3.2.4 DSS MOUSE MODEL OF COLITIS 
An outline of the colitis mouse model can be found in Figure 3.2A.  For this, 
Dextran Sulfate Sodium (DSS; MP Biomedicals, Solon, OH; m.w. 36,000-50,000) mouse 
model, 40 eight week-old C57BL/6 male mice were injected with azoxymethane (AOM; 
10 mg/kg i.p.) and divided into 4 groups.  AOM was used because this experiment was 
carried out in parallel with a colon cancer study (using AOM/DSS); thus, we wanted to 
replicate each animal model as close as possible.  Mice in Group 1 were given drinking 
water ad libitum throughout the experiment.  One week after AOM injection, 2% DSS was 
added to the drinking water for Groups 2, 3, and 4.  Groups 3 and 4 were given 0.25 mg/mL 
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and 0.5 mg/mL Cl-amidine, respectively, in the drinking water when 2% DSS was added 
to the water.  Fresh doses of DSS and Cl-amidine were added to the drinking water every 
48 h, ensuring compound stability throughout the experiment.  Colitis induction was 
evaluated during this study by monitoring body weight changes, bloody and loose stool, 
and rectal bleeding with daily observations.  We determined that colitis was being 
sufficiently induced in Group 2 as compared to Groups 1, 3, and 4 (data not shown).  We 
did not examine colon cancer as an endpoint for these experiments because we wanted to 
determine whether Cl-amidine administered in the drinking water at our doses was 
effective in suppressing DSS-induced colitis before embarking on a lengthy, expensive 
mouse model of colitis-associated colon cancer.   
0.5 mg/mL Cl-amidine is the equivalent to approximately 486 mg/day for humans.  
Our calculation of the human equivalent amount of Cl-amidine consumed by mice uses the 
body surface area normalization method (14), with the following assumptions: a typical 
mouse drinks 5 mL water daily and weighs 25 g; the average adult human weighs 60 kg.  
Therefore, 0.5 mg/mL x 5 mL drinking water/day = 2.5 mg Cl-amidine/day.  An average 
mouse weighs 25 g, therefore 2.5 mg/25 g x 1000 g/1 kg = 100 mg/kg/day.  As discussed 
by Reagan-Shaw (14), the human equivalent dose (HED, mg/kg) = animal dose (mg/kg) x 
[Animal Km/Human Km].  As such, HED (mg/kg) for mouse = 100 mg/kg x [3/37] = 8.1 
mg/kg.  If an average human adult weighs 60 kg, this equates to 8.1 mg/kg x 60 kg = 486 
mg/day for humans.  Correspondingly, 0.25 mg/mL is approximately the HED of 243 
mg/day.   
After 14 days, mice were euthanized.  For 4 mice/group, colons were flushed out 
with 1x phosphate buffered saline (PBS), opened longitudinally then incubated in 10% 
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FBS/5mM Ethylenediaminetetraacetic acid (EDTA)/Ca2+/Mg2+ free PBS for 15 min.  
Colons were shaken gently for 10 s and the single-cell suspension consisting of epithelial 
and inflammatory cells collected in the supernatant.  Trypan blue staining revealed >95% 
viable cells by microscopic observation.  Epithelial and inflammatory cells were separated 
using CD45+ magnetic cell sorting technology, according to kit instructions (Miltenyi 
BioTec, Auburn, CA).  Small aliquots of cells from each group were centrifuged, and a dry 
pellet was frozen at -80 ˚C for western blot analysis.  CD45- epithelial cells were counted, 
equalized to 1 x 106 cells, centrifuged (1,500 rpm, 5 min).  Pellets were resuspended in 
freezing media and frozen at -80 ˚C until Comet analysis.  CD45+ inflammatory cells were 
counted, equalized to 1 x 106 cells, centrifuged (1,500 rpm, 5 min.), and examined for 
oxidative bursts by chemiluminescence.  For the remaining 6 mice/group, colons were 
removed and measured.  Colons were cut longitudinally, Swiss-rolled, and fixed in 10% 
buffered formalin overnight, then processed for histopathology/immunohistochemistry by 
paraffin embedding and sectioning.   
3.2.5 QUANTIFICATION OF INFLAMMATION TO EXAMINE EFFECTS ON COLITIS  
Paraffin embedded tissues were serially sectioned, and one section from each 
mouse was stained with H&E.  Sections were microscopically examined for 
histopathologic changes, as we have done previously (15). 
3.2.6 WESTERN BLOT ANALYSIS AND ANTIBODIES 
Western blots were carried out as described previously (16).  Antibodies used include:  
iNOS (Rabbit polyclonal, diluted 1:1000; Cayman Chemicals, Ann Arbor, MI), Cox-2 
(Rabbit polyclonal, diluted 1:2000; Cayman Chemicals, Ann Arbor, MI), SOD1 (Rabbit 
polyclonal, diluted 1:2000; Abcam, Cambridge, MA), GPx1 (Rabbit polyclonal, diluted 
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1:500; Abcam, Cambridge, MA), catalase (Rabbit polyclonal, diluted 1:500; Abcam, 
Cambridge, MA), and GAPDH (Rabbit monoclonal, clone 14C10, diluted 1:1000, Cell 
Signaling, Danvers, MA).  
3.2.7 IMMUNOHISTOCHEMICAL STAINING 
For immunohistochemical staining, serial sections of mouse colon tissues 
(processed as described above) were incubated with anti-iNOS (Rabbit Polyclonal, diluted 
1:2000; Cayman Chemical, Ann Arbor, MI), catalase (Rabbit Polyclonal, diluted 1:1000; 
Abcam, Cambridge, MA), GPx1 (Rabbit Polyclonal, diluted 1:1000; Abcam, Cambridge, 
MA), and SOD1 (Rabbit Polyclonal, diluted 1:500; Abcam, Cambridge, MA).  To ensure 
even staining and reproducibility, sections were incubated by slow rocking overnight in 
primary antibodies (4 °C) using the Antibody Amplifier™ (ProHisto, LLC, Columbia, SC).  
Sections were processed with EnVision+ System-HRP kit according to kit protocols 
(DakoCytomation, Carpinteria, CA).  The positive control was colon cancer tissue and the 
negative control lacked primary antibody incubation.  Immunohistochemistry was 
quantified as described previously (17). 
3.2.8 MEASURING OXIDATIVE BURSTS 
 Oxidative bursts from inflammatory cells were measured by chemiluminescence 
according to kit directions (World Precision Instruments, Sarasota, FL); and described by 
our group previously (18). 
3.2.9 COMET ANALYSIS 
A Comet assay was performed according to kit instructions (CometAssayTM, 
Trevigen, Gaithersburg, MD).  Cells treated with hydrogen peroxide (200 M, 20 min.) 
were positive controls.  Fifty comets/treatment were captured and quantified with the 
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Automated Comet Assay Analysis System (Loats Associates, Inc., Westminster, MD).   % 
DNA Damage is defined as the % DNA in the tail.  % DNA in the tail is defined as: 
integrated tail intensity x 100/total integrated cell intensity = normalized measure of the % 
total cell DNA in the tail. 
3.2.10 STATISTICAL ANALYSIS 
 Mean differences between groups were compared by one-way ANOVA with 
Scheffe multiple comparison tests. The P-value chosen for significance in this study was 
0.05. 
3.3 RESULTS 
3.3.1 CL-AMIDINE DELIVERED THROUGH THE DRINKING SUPPRESSES DSS-INDUCED COLITIS 
 We previously shown that Cl-amidine, delivered daily by oral gavage, suppresses 
DSS-induced colitis in mice (6).  Because Cl-amidine has a relatively short half-life in mice 
(37 min) (19), we wanted to determine whether adding Cl-amidine in the drinking water 
would enable a slower delivery of similar dosages that had worked previously (6).  In our 
previous study, mice were dosed with Cl-amidine at 75 mg/kg/day by oral gavage.  Here, 
we estimate that 0.25 mg/mL and 0.5 mg/mL are equivalent to 50 mg/kg and 100 mg/kg 
daily (see calculations in Methods).  Figure 3.2B shows that delivering Cl-amidine through 
the water effectively suppresses colitis induced by AOM+DSS.  The addition of both 0.25 
mg/mL and 0.5 mg/mL are equally effective, with the histology score nearly that of the 
AOM only control group.  Similarly, Cl-amidine increased weight gain compared to 
AOM+DSS treated mice.  It is important to note, that under such conditions, Cl-amidine 
does suppress protein citrullination (20). 
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Because mouse colon length shrinks with stress, inflammation, and ulceration, 
colon lengths were measured upon euthanasia. Compared with the AOM only group 
(Group 1: 8.7±0.15cm), the length was significantly reduced in the AOM+DSS group 
(Group 2: 7.7±0.27cm). Mice consuming AOM+DSS+0.25 mg/mL Cl-amidine (Group 3) 
had a statistically significant increase in colon length (9.0±0.15 cm) compared to the 
AOM+DSS group.  Mice consuming AOM+DSS+0.5 mg/mL Cl-amidine (Group 4) had a 
statistically similar colon length (8.6±0.26 cm) to that of Groups 1 and 3, indicative of 
healthier, less inflamed colon in groups 1, 3, and 4.  
To further verify the in vivo immunosuppressive effects of Cl-amidine on colon 
inflammation, we probed colon tissues for iNOS by immunohistochemistry.  Figure 3.3 
shows representative sections of stained tissues and quantification of iNOS.  Overall, iNOS 
levels were elevated in AOM+DSS-treated mice, with staining appearing mostly in 
epithelial cells.  iNOS staining was statistically significantly reduced in the 
AOM+DSS+Cl-amidine-treated mice.  Such results both confirm and complement our 
H&E pathology results. 
3.3.2 CL-AMIDINE INHIBITS INFLAMMATORY CELL ACTIVATION AND ASSOCIATED DNA 
DAMAGE IN TARGET EPITHELIAL CELLS IN VITRO AND IN VIVO. 
Mucosal and DNA damage associated with colitis is, in part, a result of an oxidative 
burst from overactive inflammatory cells (21, 22).  Since we found that pre-incubating 
ANA-1 mouse macrophages with Cl-amidine suppressed iNOS and Cox-2 induction by 
IFN-γ (Figure 3.4A), we tested the hypothesis that PAD inhibition by Cl-amidine can 
inhibit leukocyte activation with release of free radicals through an oxidative burst, and 
resultant epithelial cell DNA damage.  Figure 3.4B shows that Cl-amidine (10 µg/mL) 
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inhibits oxidative bursts in cultured macrophages.  Cells pretreated with Cl-amidine for 12 
h have 60% less oxidative burst capacity than cells not treated with Cl-amidine.  This 
indicates Cl-amidine blunts basal oxidative bursts.  1 h after activation with IFN-γ, Cl-
amidine-treated cells have 60% of the oxidative burst capacity of untreated cells, indicating 
that Cl-amidine also protects from an induced oxidative burst.  Thereafter, cells begin 
regaining their oxidative burst capacity, presumably because of the depletion of Cl-
amidine. 
Because an oxidative burst from macrophages can induce DNA damage in target 
epithelial cells, we co-cultured ANA-1 macrophages with HCT116 colon cancer cells (see 
Methods).  Figure 3.4C shows a time-dependent increase in DNA damage, as assessed by 
Comet assay.  Cells pre-incubated with Cl-amidine were significantly protected from DNA 
damage at 4 h after the initiation of co-incubation (p< 0.01). 
We next asked whether Cl-amidine can activate anti-oxidant enzymes.  Therefore, 
we measured the levels of key anti-oxidant enzymes, catalase, GPx1, and SOD1, which are 
shown to be reduced in models of IBD (23-25).  Figure 3.5A shows that the level of each 
enzyme increases maximally when Cl-amidine is dosed at 5 µg/mL (12 µM) in ANA-1 
murine macrophages.  Also, we demonstrated that Cl-amidine treatment upregulates 
antioxidant enzymes in our mouse model of colitis as compared to AOM+DSS-treated 
mice (Figure 3.5B-D).  As expected, the AOM only treated mice had low basal levels of 
catalase and GPx1 due to no induction of inflammation.  Likewise, the AOM+DSS-treated 
mice had attenuated levels of catalase, GPx1, and SOD1 in the presence of significant 
inflammation.  To note, the AOM only group did have a higher basal level of SOD1, 
however, SOD1 levels were restored upon Cl-amidine treatment (Figure 3.5D). 
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 In order to test whether Cl-amidine inhibits an oxidative burst and associated DNA 
damage in vivo, isolated colon epithelial and inflammatory cells from mice treated with 
and without Cl-amidine (see Methods).  Figure 3.6A shows that AOM+DSS-treated mice 
have increased levels of iNOS in CD45+ and CD45- cells.  iNOS induction is attenuated in 
mice consuming Cl-amidine.  CD45+ leukocytes were examined for an oxidative burst by 
chemiluminescence and we found that Cl-amidine suppresses CD45+ cell activity in the 
colon (Figure 3.6B).  CD45- colon epithelial cells from the same mice were examined for 
DNA damage by Comet analysis.  Figure 3.6C shows DNA damage is blunted in mice 
consuming Cl-amidine.  Interestingly, but not surprisingly, there was appreciable DNA 
damage in the AOM+DSS group.  Such damage is attributed to AOM, a carcinogen capable 
of causing DNA damage in the gastrointestinal tract (26, 27).  These results indicate that 
Cl-amidine attenuates inflammatory cell activation and protects from colon epithelial cell 
damage in vivo.  Such results provide mechanistic reasoning for the ability of Cl-amidine 
to attenuate colitis-associated mucosal damage, and the potential for protection against 
colon cancer development. 
3.4 DISCUSSION 
Here we have shown that the pan-PAD inhibitor, Cl-amidine, given to mice in 
drinking water, and shown by us to block protein citrullination in mice fed Cl-amidine (20), 
suppresses colitis (Figure 3.2).  Additionally, we have shown that Cl-amidine suppresses 
an oxidative burst in leukocytes, and protects target epithelial cells from DNA damage in 
vitro (Figure 3.4) and in vivo (Figure 3.6).  Increasing evidence shows that PADs are 
involved in the citrullination of multiple target proteins.  Although there are some 
overlapping target proteins, each isozyme (PAD1-4 and PAD6) appears to target a unique 
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set of cellular proteins (28, 29).  For instance, PAD4 (the most well-studied PAD isozyme) 
is involved in gene regulation and apoptosis, acting as a transcriptional co-regulator for 
p21, p53, p300, CIP1, ELK1, ING4, and nucleophosmin (30-34).  Because Cl-amidine is 
a pan-PAD inhibitor (8), it is likely that it suppresses the citrullination of many of these 
PAD target proteins. 
Because citrullination is an inflammation-dependent event (10), and we have 
previously shown (and show here) that Cl-amidine suppresses colon inflammation (Figure 
3.2) (6), it is likely that citrullination of proteins specifically involved in colitis drives 
inflammation.  Accordingly, we have shown here that PAD inhibition by Cl-amidine 
suppresses ROS release by inflammatory cells.  This brings up the intriguing possibility 
that enzymes/proteins directly involved in ROS production are affected by citrullination.  
Such enzymes/proteins include not only TNF-α [a major target for treatment of IBD in 
humans that has been shown to be citrullinated, resulting in a change in activity (35)], but 
also downstream targets, such as iNOS and Cox-2; both of which were suppressed by Cl-
amidine (Figures 3.3, 3.4 and 3.6).  Our finding that catalase, GPx1 and SOD1 are all 
elevated by Cl-amidine in vitro and in vivo (Figure 3.5) is also consistent with the 
hypothesis that these anti-oxidant enzymes are mechanistically involved in the crossroads 
of Cl-amidine and its’ ability to suppress an oxidative burst.  Since Cl-amidine induces p53 
(30, 36), and p53 drives the expression of anti-oxidant enzymes (37-42), potentially p53 
repression by PADs (either by direct or upstream citrullination) is suppressing the ability 
of p53 to activate anti-oxidant enzymes.  This hypothesis, though, would have to be tested. 
 In summary, we have shown that the pan-PAD inhibitor, Cl-amidine through the 
drinking water, is a viable treatment strategy for colitis.  Our data reveal that Cl-amidine 
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directly inhibits leukocyte activation and target epithelial DNA damage within the colon.  
Due to the strong link between chronic DNA damage and increased cancer risk, we are 
carrying out separate, long-term studies to explore the hypothesis that Cl-amidine protects 
mice from inflammation-driven colon cancer.  Further studies will also explore whether 
Cl-amidine works upstream of the colon in peripheral blood cells or lymphoid tissues.  
Indeed, other biological therapies can cause cellular apoptosis within spleens of treated 
mice (43).  Here, we present the first line of evidence that a pan-PAD small molecule 
inhibitor (Cl-amidine) has anti-inflammatory properties in a colitis mouse model, with the 
ability to suppress leukocyte activation and prevent colon epithelial DNA damage both in 
vitro and in vivo.  
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FIGURES 
 
 
Figure 3.1. Structure of the pan-PAD inhibitor, Cl-amidine. 
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Figure 3.2. A) Outline of the AOM/DSS mouse model of colitis used in this study. B) 
Effects of Cl-amidine on the colon histology score in the acute AOM/DSS colitis model. 
Six mice from each group described in Materials and Methods were euthanized on day 14, 
and colons were measured and harvested. Then the histology score was determined. Weight 
was recorded every 48 hours during the 14-day experiment. Values represent the mean ± 
S.E. of the mean. Representative H&E-stained colons are shown for each group. 
*Significant difference from the AOM + DSS group (P < 0.01). 
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Figure 3.3. iNOS levels are reduced in the colons of mice treated with Cl-amidine. Six 
mice from each of the indicated groups were euthanized on day 14, and colons were 
harvested from each animal and stained with iNOS as described in Materials and Methods. 
A) Immunoreactivity score (IRS) for each group. Values represent the mean ± S.E. 
*Significant difference from the AOM + DSS only group (P < 0.01). B) Representative 
sections of indicated group. Positive staining is brown colored. (400x magnification). 
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Figure 3.4. Cl-amidine attenuates the activation of macrophages and protects from 
DNA damage in target epithelial cells in vitro. A) iNOS and Cox-2 induction after 
treatment of ANA-1 mouse macrophages with IFN-γ. Numbers below each blot represent 
the GAPDH-adjusted density of each band, with the control (0 hour, no treatment) being a 
baseline of 1.0. The observation that for both markers (iNOS and Cox-2) density is lower 
in unstimulated cells exposed to Cl-amidine (0 hour, +10 µg/ml Cl-amidine, 5th lane) 
suggests Cl-amidine inhibits basal activity of macrophages. Accordingly, it also inhibits 
the activation of macrophages. B) An oxidative burst in ANA-1 mouse macrophages is 
attenuated by pretreatment with Cl-amidine (10 µg/ml). Chemiluminescence was measured 
as described in Materials and Methods. Results were compared with no Cl-amidine control 
(± S.E.). C) In the presence of an oxidative burst, target epithelial cells (HCT116 colon 
cancer cells) pretreated with 10 µg/ml Cl-amidine are protected from DNA damage. 
Results are represented as the mean Comet tail moment ± S.E., scoring 50 comets/treatment 
group. Representative images of Comets in each treatment group are shown above each 
bar graph. *Significant difference from the untreated (No Cl-amidine) macrophages that 
were cocultured for 4 hours (P < 0.01). 
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Figure 3.5. Cl-amidine induces antioxidant enzymes (catalase, GPx1, SOD1) in IFN-
γ–stimulated ANA-1 mouse macrophages and in vivo. A) ANA-1 mouse macrophage 
cells were pretreated with 0–10 µg/ml Cl-amidine for 12 hours and then cells were 
stimulated with IFN-γ for 8 hours. Antioxidant enzymes of interest were suppressed in 
activated cells pretreated with 10 µg/ml (lane 4). B–D) Mice from each of the indicated 
groups were euthanized on day 14, and colons were harvested from each animal and stained 
with catalase (B), GPx1 (C), and SOD1 (D) as described in Materials and Methods. 
Immunoreactivity scores (IRS) are shown for each group. Values represent the mean ± S.E. 
Significance is compared with the AOM + DSS only group: *P < 0.05; **P < 0.01; ***P 
< 0.005. Representative sections of each group were taken at 400x magnification, and 
positive staining is brown colored. 
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Figure 3.6. Cl-amidine attenuates the activation of white blood cells and protects from 
DNA damage in target epithelial cells in vivo. Mice were injected with AOM (10 mg/kg), 
then 1 week later they were given either water ad libitum or 2% DSS in the drinking water 
for 14 days as described in Materials and Methods and in Figure 3.2. A) Protein lysates 
from scraped mucosa of the colon (4 mice per group; lysates were combined) were 
examined for iNOS and GAPDH (internal control). Mice consuming 2% DSS had 
activation of only iNOS in both CD45+ and CD45- cells. Mice consuming Cl-amidine + 
2% DSS had iNOS attenuated in both cell types. B) After column separation of 
inflammatory cells from mucosal cells, we examined an oxidative burst of CD45+ 
inflammatory cells (4 mice per group). Mice consuming Cl-amidine + DSS exhibit CD45+ 
inflammatory cells with attenuated activity compared with mice on 2% DSS only. 
Chemiluminescence was measured as described in Materials and Methods and expressed 
as mean (± S.E.) relative light units (RLU) per 1 x 106 cells. *Significant difference from 
the AOM + DSS–only group (P < 0.05). C) Mucosal epithelial cells were examined for 
DNA damage by Comet analysis. Results are presented as the mean (± S.E.) tail moment 
from 200 Comets taken from 4 mice per group. *Significant difference from the AOM + 
DSS–only group (P < 0.01). Representative Comets for each group are shown.  
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CHAPTER 4 
MOLECULAR TARGETING OF PROTEIN ARGININE DEIMINASES TO SUPPRESS 
COLITIS AND PREVENT COLON CANCER 
ABSTRACT: Ulcerative colitis (UC) is a chronic disease, in which the lining of the colon 
becomes inflamed and develops ulcers leading to abdominal pain, diarrhea, and rectal 
bleeding.  The extent of these symptoms depends on disease severity.  The protein arginine 
deiminase (PAD) family of enzymes converts peptidyl-Arginine to peptidyl-Citrulline 
through citrullination.  PADs are dysregulated, with abnormal citrullination in many 
diseases, including UC and colorectal cancer (CRC).  We have developed the small 
molecule, pan-PAD inhibitor, Chlor-amidine (Cl-amidine), with multiple goals, including 
treating UC and preventing CRC.  Building off our recent results showing that: 1) Cl-
amidine suppresses colitis in vivo in a dextran sulfate sodium (DSS) mouse model; and 2) 
Cl-amidine induces microRNA (miR)-16 in vitro causing cell cycle arrest, we tested the 
hypothesis that Cl-amidine can prevent tumorigenesis and that miR-16 induction, by Cl-
amidine, may be involved in vivo.  Consistent with our hypothesis, we present evidence 
that Cl-amidine, delivered in the drinking water, prevents colon tumorigenesis in our 
mouse model of colitis-associated CRC where mice are given carcinogenic azoxymethane 
(AOM), followed by multiple cycles of 2% DSS to induce colitis.  To begin identifying 
mechanisms, we examined the effects of Cl-amidine on miR-16.  Results show miR-16
                                                          
* Erin E. Witalison, Xiangli Cui, Corey P. Causey, Paul R. Thompson, and Lorne J. 
Hofseth.  Oncotarget.  2015; 6(34); 36053-36062.  Reprinted with permission. 
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 suppression during the colitis-to-cancer sequence in colon epithelial cells, which was 
rescued by drinking Cl-amidine.  Likewise, Ki67 and cellular proliferation targets of miR-
16 (Cyclins D1 and E1) were suppressed by Cl-amidine.  The decrease in cell proliferation 
markers and increase in tumor suppressor miRNA expression potentially define a 
mechanism of how Cl-amidine is suppressing tumorigenesis in vivo. 
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4.1 INTRODUCTION  
 Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that 
affects millions of people worldwide and causes symptoms of abdominal pain, diarrhea, 
and rectal bleeding.  Due to the chronic inflammatory state of UC, which causes cyclical 
oxidative stress and leads to DNA damage, patients with UC are at a higher risk of 
developing colorectal cancer (CRC) (1).  The probability of developing CRC increases 
yearly once UC develops, with up to an approximate 20% incidence after 30 years (1, 2).  
Current treatment options help to treat the symptoms, prevent flares, and heal the damaged 
colon; however, the treatment outcomes are often marginal, patients become refractory, 
and there are dangerous adverse side effects.  Therefore, we continue to investigate novel 
therapies showing reduced toxicity and more substantial efficacy in treating UC and 
preventing CRC. 
The protein arginine deiminase (PAD) family of enzymes converts peptidyl-
Arginine to peptidyl-Citrulline through a process called ‘citrullination’ (3).  There are five 
isozymes found in mammals (PAD1-4 and 6), with 70-95% homology in their amino acid 
sequence (4).  The PAD isozymes are encoded by a cluster of homologous genes found on 
Chromosome 1 in humans (4, 5).  Citrullination can affect protein-protein interactions, 
hydrogen bond formation, and protein structure due to the shift from the positively charged 
peptidyl-Arginine to the neutral peptidyl-Citrulline (5).  At physiological activity levels, 
PADs regulate many cell signaling pathways including differentiation, apoptosis, and gene 
transcription (6).  However, over the past decade, it is becoming increasingly apparent that 
aberrant PAD activity is involved in many human inflammatory diseases such as: 
rheumatoid arthritis, Alzheimer’s disease, and multiple sclerosis (3, 7-10).  Concerning our 
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study, PADs, especially PAD4, are found to be dysregulated in UC and CRC (11-14).  In 
UC and other chronic inflammatory, autoimmune diseases, it is thought that the 
accumulation of citrullinated proteins is what leads to an abnormal immune response that 
further exacerbates the inflammatory response (6).   
We have developed a novel, small molecule inhibitor of PADs, named N-α-
benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide or Chlor-amidine (Cl-amidine).  
Cl-amidine prevents citrullination by covalently modifying a conserved cysteine residue in 
the active site of the PADs, causing irreversible inactivation of the enzyme (6).  Cl-amidine 
is an excellent candidate drug for our CRC prevention studies because it: 1) exhibits little 
toxicity at doses we use here in vitro and in vivo; 2) displays no immunosuppressive effects 
in multiple disease models associated with PAD dysregulation; 3) effectively suppresses 
colitis in mice when given by oral gavage; and 4) increases tumor suppressor microRNA 
(miRNA) levels in vitro (14-17).  Based on these precedents, we tested the hypothesis that 
Cl-amidine can prevent tumorigenesis in the azoxymethane (AOM)/dextran sulfate sodium 
(DSS) mouse model of colitis-associated CRC.  Mechanistic insight is also gained by 
examining the levels of miRNA changes during this process.      
4.2 RESULTS 
4.2.1 CL-AMIDINE SUPPRESSES AOM/DSS-INDUCED TUMORIGENESIS IN MICE 
To ensure that 2% DSS was effectively causing colitis in the treated mice, we 
determined the histology score of four euthanized mice (per group) at day 35.  In Figure 
4.1B, histology scores for ulceration and inflammation indicate that the AOM + DSS only 
group does have a significantly higher score than the AOM only group.  As expected at 
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this time point, despite the varying severity of colitis in the treatment groups, none of the 
mice had developed tumors. 
 At day 70, mice were euthanized, and we recorded the number mice with tumors 
(Table 4.1) and the average number of tumors per mouse in each group (Figure 4.2A; tumor 
multiplicity).  We also measured the size of each tumor (Table 4.1) and captured 
representative images of the methylene blue stained colons (Figure 4.2B).  No tumors were 
found in the control AOM only mice and, as predicted, the AOM + DSS only group (Group 
2: 2.8 ± 0.68 tumors/animal) had the highest tumor multiplicity.  Mice treated with Cl-
amidine (Group 3: 0.07 ± 0.07 tumors/animal; Group 4: 0.67 ± 0.23 tumors/animal) had 
significantly reduced tumor multiplicity than the AOM + DSS only group.  Interestingly, 
there was a significant difference in tumor multiplicity (p<0.05) between the Cl-amidine 
treated groups where the higher dosage group (Group 4: 0.25 mg/mL Cl-amidine) had a 
higher tumor multiplicity than the lower dosage group (Group 3: 0.05 mg/mL Cl-amidine).  
Although at this point we are unable to explain this observation, perhaps a certain basal 
level of citrullination is necessary to carry out functions, such as apoptosis.  Since the 
citrullination of proteins involved in apoptosis (e.g. vimentin, nucleophosmin, nuclear 
lamin C) facilitates the process of apoptosis (18-21), the higher dose of Cl-amidine may be 
inhibiting the citrullination necessary for the progression of apoptosis and aiding in the 
development of tumors, thus accounting for the increased tumor incidence.  Nevertheless, 
the overall results from this model show for the first time that Cl-amidine is capable of 
preventing tumorigenesis associated with chronic colitis. 
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4.2.2 CL-AMIDINE INCREASES MIR-16 EXPRESSION AND DOWNREGULATES CELL 
PROLIFERATIVE MIR-16 TARGETS IN MICE  
We have previously shown that Cl-amidine increases miR-16 expression in a p53-
dependent manner resulting in a cell cycle arrest in vitro (17).  Since the inhibition of cell 
proliferation is a goal of many anti-cancer drug therapies, we hypothesized that Cl-amidine 
is preventing tumorigenesis by increasing miR-16 expression in vivo.  To test this, we 
measured miR-16 expression levels in isolated colon epithelial (CD45-) cells at day 35 (see 
methods).  We chose to investigate the miR-16 expression levels at the day 35 time point 
because we were interested in the mechanism preventing tumorigenesis at day 70.  Figure 
4.3 shows the relative fold change in miR-16 levels in the epithelial cells.  Consistent with 
our previously published in vitro data (17) and our current hypothesis, miR-16 expression 
in the AOM + DSS only group was significantly lower than the AOM only group and both 
Cl-amidine treated groups.  Furthermore, the lower level of miR-16 expression in epithelial 
cells from the higher dosage group (0.25 mg/mL Cl-amidine), compared to the lower 
dosage group (0.05 mg/mL Cl-amidine), is highly suggestive of a direct correlation 
between the expression level of miR-16 and tumor incidence; however, the cause of this 
variability between Cl-amidine treatment groups is currently unknown. 
 miR-16 has multiple cell proliferation targets, such as Cyclin D1 and Cyclin E1; 
supporting the premise that it is a tumor suppressor miRNA (17, 22-25).  If miR-16 
expression is increased with Cl-amidine treatment (Figure 4.3), then we expect to see the 
downregulation of these cell proliferation targets of miR-16.  Indeed, we confirmed that 
protein expression of Cyclins D1 and E1 was suppressed in the Cl-amidine treated groups 
when compared to the AOM + DSS only group (Figures 4.4A and B). To further verify the 
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repression of cell proliferation in the mice treated with Cl-amidine, we performed IHC 
staining for the cell proliferation marker, Ki67, in colons collected at day 35 (Figure 4.4C).  
In the colons collected at day 35, the IRS of the AOM + DSS only groups were significantly 
higher than the control AOM only groups (Figure 4.4A-C).  For Cyclin D1 and Ki-67 
stained colon sections, the lower dose Cl-amidine group (0.05 mg/mL) had a lower IRS 
than the AOM + DSS only group; however, the group receiving 0.25 mg/mL Cl-amidine 
was not significantly lower.  Interestingly, the IRS values of Cyclin D1 and Ki67 staining 
at day 35 revealed a similar trend to the tumor incidence and miR-16 expression levels in 
colon epithelial cells.  For Cyclin E1 stained colon sections, the groups treated with Cl-
amidine both had lower IRS values than the AOM + DSS only group, but the lower dose 
Cl-amidine group (0.05 mg/mL) was not significantly less.  These results are consistent 
with the hypothesis that Cl-amidine is suppressing tumorigenesis in our mouse model by 
inhibiting cell proliferation via increased miR-16 expression. 
4.3 DISCUSSION 
In this study, we provide evidence that Cl-amidine, a small molecule inhibitor of 
PADs, administered to mice in drinking water suppresses colitis (Figure 4.1) and 
tumorigenesis (Figure 4.2; Table 4.1).  To uncover the mechanism by which Cl-amidine is 
acting, we revealed that Cl-amidine increases miR-16 expression in colon epithelial cells 
(Figure 4.3).  Likewise, Cl-amidine treatment decreases protein expression of the miR-16 
targets, Cyclins D1 and E1, and the cell proliferation marker, Ki67 (Figure 4.4).  Figure 
4.5 depicts the unique mechanism by which Cl-amidine prevents the tumorigenesis of CRC 
in our mouse model. 
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 PADs are calcium-dependent.  Therefore, they are usually inactive under 
physiological levels (10-8 to 10-6 M); and only activating during certain events (i.e. 
apoptosis and terminal epidermal differentiation) where calcium levels are above 
physiological concentrations (5, 18).  Interestingly, and important to this study, patients 
with active Crohn’s disease or UC have moderately higher Ca2+ levels than healthy controls 
(26).  Not surprisingly, then, citrullination (the post-translationally modified product of 
active PADs) is elevated in colitis (27).  During apoptosis and terminal epidermal 
differentiation, PADs are found to citrullinate structural proteins, such as vimentin and 
filaggrin, causing partial unfolding of the proteins (5, 18).  The citrullination of these 
structural proteins promotes the overall degradation of the cells during cell death.  PADs, 
specifically PAD4, have also been found to regulate gene expression (28-33).  Many of the 
genes that the PADs regulate are involved in the progression of the p53 pathway, including 
ING4, p300, and HDAC2 (30-32).  With the involvement of PADs in pathways that are 
crucial for proper cell growth and cell death, it is readily apparent that aberrant PAD 
activity can lead to deleterious consequences (e.g. abnormal DNA damage repair response, 
protein misfolding, protein inactivation).   
Additionally, citrullination controls the expression of tumor suppressing miRNAs.  
miRNAs are regulators of genes that control various cell signaling processes, such as cell 
proliferation, apoptosis and stress response (34).  As a result of an inflammatory response, 
such as that of UC, miRNAs can be altered and expression levels can fluctuate (35).  
Although other miRNAs have been found associated with either mouse or human UC, we 
focused here on miR-16 because our previous in vitro data showed that Cl-amidine induces 
miR-16 expression and decreases the expression of several miR-16 targets (i.e. Cyclins D1, 
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D2, D3, E1, and CDK6) involved in the progression through the cell cycle (17).  Likewise, 
miR-16 is found at lower levels in CRC than in normal tissue (36).  One prospective 
pathway through which Cl-amidine may be upregulating miR-16 expression levels 
involves the tumor suppressor p53.  p53 boosts the post-transcriptional maturation of miR-
16 and Cl-amidine is found to increase miR-16 expression in a p53-dependent manner in 
vitro (17, 37-39). 
In summary, we have shown that Cl-amidine suppresses colitis and, in this current 
study, suppresses tumorigenesis in mice given Cl-amidine dosages in drinking water (14).  
Our current in vivo study is a substantial extension of our previous mechanistic in vitro 
data and suggests that increased miR-16 expression in mice treated with Cl-amidine results 
in decreased tumor formation (17).  When miR-16 is downregulated, this relieves its 
inhibition of cell proliferative targets, like Cyclin D1 and E1.  Because our results 
demonstrate that Cl-amidine can suppress these targets of miR-16, this verifies the activity 
of miR-16 throughout our model.  These findings display a significant development in our 
knowledge of in vivo mechanisms by which PAD inhibition can suppress colon cancer.  
Future studies will explore the mechanism(s) by which Cl-amidine is increasing miR-16 
expression and will determine optimum dosages for preventing tumorigenesis.  Overall, 
this study presents Cl-amidine as a viable cancer preventative therapy against colitis-
associated colorectal cancer and provides an innovative mechanism of action involving the 
upregulation of miR-16, ultimately leading to decreased cell proliferation and prevention 
of tumorigenesis in vivo. 
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4.4 MATERIALS AND METHODS 
4.4.1 CL-AMIDINE 
The synthesis of Cl-amidine has previously been described (6, 40). 
4.4.2 AOM/DSS MOUSE MODEL OF COLITIS-ASSOCIATED COLORECTAL CANCER 
This mouse model of colorectal cancer is outlined in Figure 4.1A.  C57BL/6 male 
mice (8-12 weeks old; Jackson Laboratory) were used in accordance with protocols 
approved by the Institutional Animal Care and Use Committees of University of South 
Carolina.  AOM (10 mg/kg) was injected into each mouse via intraperitoneal injection.  
The mice were divided into four groups where Group 1 received drinking water ad libitum 
throughout the experiment.  One week after AOM injection, Groups 2-4 began cycles of 
2% DSS (MP Biomedicals, Solon, OH; m.w. 36 000 -50 000) given in the drinking water 
for 70 days.  Groups 2-4 were subjected to three cycles, each consisting of one week with 
2% DSS in the water followed by two weeks of normal drinking water.  The DSS cycles 
were aimed to simulate the active inflammatory and remission states of UC.  Groups 3 and 
4 were administered 0.05 mg/mL and 0.25 mg/mL Cl-amidine, respectively, daily in the 
drinking water beginning at day 14 and ending at day 70. 
0.05 mg/mL and 0.25 mg/mL, which is the equivalent of 10 mg/kg/day and 50 
mg/kg/day per mouse, respectively; or the human daily equivalent of 48.6 mg and 243 mg, 
respectively.  Calculations are as follows: assuming an average mouse weighs 25 g and 
drinks approximately 5 mL per day, then 0.25 mg / 25 g x 1000 g / 1 kg = 10 mg/kg daily.  
The human equivalent dose (HED, mg/kg) = animal dose (mg/kg) x [Animal Km / Human 
Km] (41).  The HED (mg/kg) for mouse = 10 mg/kg x [3/37] = 0.81 mg/kg.  Therefore, 
assuming an adult human weighs approximately 60 kg on average, the human equivalent 
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is 0.81 mg/kg x 60 kg = 48.6 mg daily.  Using the same equations, the 0.25 mg/mL mouse 
dosage is approximately the equivalent of 243 mg daily for humans.  We chose these doses 
because our previous work has shown that 5 - 75 mg/kg/mouse per day was effective in a 
dose-responsive manner at suppressing DSS-induced colitis in mice (14).  Since 5 
mg/kg/day was only modestly effective, and 75 mg/kg/day is the Maximal Tolerable Dose, 
we wanted to investigate the potency of multiple doses within this range (14, 15).  Thus we 
chose 0.05 mg/mL and 0.25 mg/mL delivered in the drinking water.  We reasoned Cl-
amidine would work better delivered in the drinking water because Cl-amidine has a short 
half-life in vivo (15).  Therefore delivering the same amount throughout the day over a long 
period time (in water) versus a bolus amount (oral gavage) would be a better method with 
short-life compounds.  We also determined that Cl-amidine is stable in DSS-spiked water 
for 48 h (data not shown) and the mice drink approximately the same amount of water daily 
regardless of treatment (Figure 4.6). 
At day 35, after 1.5 cycles of DSS, 10 mice from each group (1-4) were euthanized 
to ensure that the DSS was effective and for further analysis.  Colons from each mouse 
were removed, cut longitudinally, and washed with 1x phosphate buffered saline (PBS).  
The colons from four mice from each group were Swiss-rolled, fixed in 10% buffered 
formalin overnight, paraffin embedded, and then sectioned for 
histopathology/immunohistochemistry.  The colons from the remaining six mice/group 
were incubated in 10% fetal calf serum/5 mM ethylenediaminetetraacetic acid 
(EDTA)/Ca2+/Mg2+ free PBS for 15 min.  Colons were then shaken gently for 10 sec and 
the single cell suspension, consisting of epithelial and inflammatory cells, collected in the 
supernatant.  Inflammatory cells were separated from epithelial cells using CD45+ 
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magnetic microbeads that select for the inflammatory cells, according to kit instructions 
(mouse CD45+ MicroBeads, Miltenyi Biotec, Auburn, CA).  These separated cells were 
immediately processed for miRNA analysis to avoid any breakdown of the RNA integrity.  
At day 70, the remaining 15 mice from each of the groups were euthanized.  Colons 
were removed, cut longitudinally, and washed with 1x PBS.  Tumor incidence and size 
were recorded for each colon.  Colons from each group were processed for 
histopathology/immunohistochemistry in the same manner as the colons harvested at day 
35. 
4.4.3 QUANTIFICATION OF INFLAMMATION 
Colons prepared for histopathology were stained with hematoxylin and eosin 
(H&E).  Sectioned H&E stained samples were examined microscopically and scored as 
previously described (14).  Briefly, the histology score for a sample was determined by 
adding the scores for inflammation severity, inflammation extent, and crypt damage; then, 
multiplying by the score for percent area involvement.  The inflammation severity was 
scored on a scale of 0-3: 0 (no inflammation), 1 (minimal), 2 (moderate), and 3 (severe).  
Inflammation extent was scored on a scale of 0-3: 0 (no inflammation), 1 (mucosa only), 2 
(mucosa and submucosa), and 3 (transmural).  Crypt damage was scored on a scale of 0-4: 
0 (no crypt damage), 1 (one-third of crypt damaged), 2 (two-thirds damaged), 3 (crypts lost 
and surface epithelium intact), and 4 (crypts lost and surface epithelium lost).  Percent area 
involvement was scored on a scale of 0-4: 0 (0% involvement), 1 (1-25%), 2 (26-50%), 3 
(51-75%), and 4 (76-100%).  The minimum possible score is 0 and the maximum possible 
score is 40.  
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4.4.4 MIR-16 EXPRESSION 
Total miRNA was extracted from separated inflammatory (CD45+) and epithelial 
(CD45-) cells according to miRNeasy Mini Kit instructions (Qiagen).  RNA concentration 
and stability were measured by the Nanodrop 2000 (Nanodrop, Wilmington, DE).  10 ng 
of total RNA were used to make cDNA using the TaqMan MicroRNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA) according to kit instructions.  We 
also used hsa-miRNA-16 primers for miR-16 detection and small nuclear protein RNU6B 
(U6) for normalization (Applied Biosystems, Foster City, CA).  Quantitative Real-Time 
PCR to measure miR-16 and U6 was performed using the TaqMan miRNA Assay (Applied 
Biosystems, Foster City, CA) with the 7300 PCR Assay System (Applied Biosystems, 
Foster City, CA).  The relative fold change (FC) of miR-16 expression, as compared to U6 
expression, was determined based on the comparative threshold cycles (Ct) of miR-16 and 
U6.  All samples were analyzed in triplicate. 
4.4.5 IMMUNOHISTOCHEMICAL STAINING 
Paraffin-embedded sections of mouse colonic tissue were incubated (4˚C) in Cyclin 
D1 (Rabbit monoclonal, cat# TA307019, diluted 1:100, Origene, Rockville, MD), Cyclin 
E1 (rabbit polyclonal, cat# TA311853, diluted 1:1000, Origene, Rockville, MD), and anti-
Ki67 (Rabbit polyclonal, cat# PA5-19462, diluted 1:5000, Pierce, Rockford, IL) primary 
antibodies by slow rocking overnight with Antibody Amplifier (ProHisto, Columbia, SC) 
to ensure even and reproducible staining.  Samples were then processed using the 
EnVision+ System HRP kits (DAKO, Carpinteria, CA) according to kit instructions.  The 
chromagen, diaminobenzidine, was added and then the samples were counterstained with 
methyl green.  Stained tissues were objectively scored based on two criteria: 1) percentage 
  
109 
of tissue stained, and 2) the staining intensity.  The percentage of tissue stained was scored 
on a scale of 0-5: 0 (0% positive staining), 1 (<10%), 2 (11-25%), 3 (26%-50%), 4 (51%-
80%), or 5 (>80%).  Staining intensity was scored on a scale of 0-3: 0 (Negative staining), 
1 (Weak), 2 (Moderate), or 3 (Strong).  Scores from each criteria were multiplied to get the 
final immunoreactivity score (IRS). 
4.4.6 STATISTICAL ANALYSIS 
Mean differences between groups were compared by one-way ANOVA with Scheffe 
multiple comparison tests.  The p-value chosen for significance in this study was 0.05.  
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TABLES 
Table 4.1. Tumor incidence, multiplicity, and size are reduced in the colons of mice 
treated with Cl-amidine.  Tumor incidence (the number of mice per group with tumors) 
is shown alongside the percentage of mice with tumors.  The average number of tumors 
per mouse (tumor multiplicity) is shown and is also divided based on size (<1 mm and >1 
mm at the largest dimension).  Tumor multiplicity based on tumor size is given as mean ± 
standard error of the mean (SE).  Significant differences from the AOM + DSS only group 
are indicated by * (p<0.05) and *** (p<0.005). 
 
 
Tumor 
Incidence 
Average # 
of tumors 
Average tumor 
multiplicity <1mm 
Average tumor 
multiplicity >1mm 
AOM 0 (0%) 0 0 ± 0* 0 ± 0*** 
AOM + DSS 13 (86.7%) 2.80 0.67 ± 0.37 2.13 ± 0.53 
AOM + DSS + 
0.05mg/ml Cl-amidine 
1 (7.1%) 0.07 0 ± 0* 0.07 ± 0.07*** 
AOM + DSS + 
0.25mg/ml Cl-amidine 
7 (46.7%) 0.67 0 ± 0* 0.67 ± 0.23* 
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FIGURES  
 
Figure 4.1. A) Outline of the AOM/DSS mouse model of colorectal cancer used in this 
study.  B) Histology scoring of colon tissue samples from the AOM/DSS model of colon 
cancer at 35 days.  Mice from each group were euthanized at day 35 and day 70 as described 
in the methods.  Colons were harvested and processed to determine the histology score at 
day 35.  Values represent the mean ± SE.  Representative H&E stained colon sections (100x 
magnification) are shown for each group.  Arrows indicate areas of inflammation.  
Significant differences from the AOM + DSS only group are indicated by * (p<0.05), ** 
(p<0.01), and *** (p<0.005). 
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Figure 4.2. Tumor multiplicity is reduced in the colons of mice treated with Cl-
amidine.  Mice from each group were euthanized at day 70 as described in the methods.  
Colons were removed and cut longitudinally.  A) Tumor multiplicity in the AOM/DSS 
model of colon cancer at 70 days.  Significant differences from the AOM + DSS only group 
are indicated by *** (p<0.005).  B) Representative methylene blue stained colons are 
shown for each group.  Arrows indicate tumors.   
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Figure 4.3. MiR-16 expression is increased in the colon epithelial cells of mice treated 
with Cl-amidine.  Mice from each group were euthanized at day 35 and colons were 
removed to be processed to separate the colon inflammatory cells from the epithelial cells 
via magnetic microbeads.  Then, as described in the methods, total RNA was extracted and 
primed to measure miR-16 expression using qPCR.  MiR-16 expression across the 
treatment groups was quantified as the relative fold change as compared to AOM only.  
MiR-16 expression in colon epithelial (CD45-) cells at day 35 in the AOM/DSS model of 
colon cancer is shown.  Significant differences from the AOM + DSS only group are 
indicated by * (p<0.05) and *** (p<0.005). 
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Figure 4.4. Cell proliferation proteins (Cyclin D1, Cyclin E1, and Ki67) are 
downregulated in mice treated with Cl-amidine.  Colons from 4 mice per group were 
euthanized at day 35 and processed for IHC analysis.  IRS of colons at day 35 stained with 
(A) Cyclin D1, (B) Cyclin E1, both known targets of miR-16, and (C) Ki-67, a cell 
proliferation marker.  Representative sections of stained colons (400x total magnification).  
Significant differences from the AOM + DSS only group are indicated by * (p<0.05), ** 
(p<0.01), and *** (p<0.005).   
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Figure 4.5. Proposed mechanism of action for Cl-amidine preventing CRC.  As 
evidenced in the results produced in this manuscript, Cl-amidine upregulates miR-16 
expression in mice through PAD inhibition.  At this point, the cell proliferation targets 
(Cyclin D1 and E1) of miR-16 are downregulated, accounting for the decreased 
tumorigenesis found at the endpoint of our study. 
*** 
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Figure 4.6. Average water intake for mice given 2% DSS and Cl-amidine treatments.  
Mice were given indicated treatments in water to represent treatments used in the in vivo 
model of colitis-associated colorectal cancer.  Daily water consumption was measured for 
7 days (Normal water and DSS only groups) and 10 days (DSS + Cl-amidine groups).  No 
significant differences were reported between the groups measured. 
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CHAPTER 5 
EPIGENETIC REGULATION OF THE TUMOR SUPPRESSOR MIRNA, MIR-16, BY 
CL-AMIDINE  
 
ABSTRACT: Protein arginine deiminases (PADs) are a family of enzymes that catalyze 
citrullination, the post-translational conversion of peptidyl-arginine to peptidyl-citrulline.  
The resulting shift from the neutral arginine to the positive citrulline can interrupt hydrogen 
bond formation and protein-protein interactions with consequential effects on protein 
function.  PADs and citrullination are associated with the regulation of genes and apoptosis 
under physiological conditions; however, elevated levels of citrullinated proteins are 
implicated in the initiation and progression of many inflammatory diseases, including 
ulcerative colitis and various cancers.  Due to the involvement of PADs in many 
pathological conditions, PAD inhibitors have been developed to prevent and treat abnormal 
PAD activity.  One such small molecule inhibitor of PADs, Cl-amidine, targets the four 
active isozymes of PADs by covalent modification of the active site of the enzymes.  Our 
previous in vitro studies using microarray analysis of miRNAs revealed that only a small 
subset of miRNAs are affected by Cl-amidine, instead of global miRNA regulation.  The 
most significantly upregulated miRNA by Cl-amidine was miR-16, a putative tumor 
suppressor miRNA with cell cycle targets.  The aim of our current study is to understand 
how Cl-amidine is targeting select miRNAs, like miR-16.  One hypothesis explores the 
epigenetic regulation of miRNAs, specifically by methylation-mediated gene silencing.  
DNA methylation is catalyzed by DNA methyltransferases (DNMTs), a family of enzymes 
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including DNMT1, DNMT3A, and DNMT3B.  DNMTs regulate genes by methylating 
CpG islands located in the promoter regions, while aberrant hypermethylation, possibly 
caused by citrullination of DNMTs, can trigger methylation-mediated gene silencing of 
targeted genes and even miRNAs.  DNMT hyperactivity and tumor suppressor miRNA 
downregulation are both associated with various cancers.  We propose that abnormal 
DNMT activity is resulting in the hypermethylation of the miR-16 promoter and is causing 
its suppression in cancer.  Our results indicate that DNMT1 can be citrullinated, perhaps 
contributing to abnormal DNMT activity.  We also found that inhibition of DNMTs was 
able to rescue miR-16 expression to a comparable level seen upon inhibition of 
citrullination.  Ultimately, Cl-amidine was able to reduce the methylation of the miR-16 
promoter as tested with methylation-specific PCR.  Altogether, our current study 
establishes a novel epigenetic facet of Cl-amidine and provides further insight into the 
complex pathways that are involved in cancer progression.  
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5.1 INTRODUCTION 
Protein arginine deiminases (PADs) are a family of enzymes that catalyze the 
posttranslational modification, citrullination.  Citrullination is the conversion of peptidyl-
arginine to peptidyl-citrulline, resulting in a change in charge from the neutral arginine to 
the positive citrulline residue.  Shifts in amino acid charge can interrupt hydrogen bond 
formation and protein-protein interactions with consequential effects on protein function.  
PADs and citrullination are associated with regulation of genes, apoptosis, and cellular 
structure under typical physiological conditions (1-5).  In contrast, elevated levels of 
citrullinated proteins are implicated in the initiation and progression of many inflammatory 
diseases, including multiple sclerosis (6), rheumatoid arthritis (7, 8), ulcerative colitis (9, 
10), and various cancers (11).   
Due to the involvement of PADs in many pathological conditions, PAD inhibitors 
have been developed to prevent and treat abnormal PAD activity.  One such small molecule 
inhibitor of PADs, N-α-benzoyl-N5-(2-chloro1-iminoethyl)-L-ornithine amide (Cl-
amidine), targets the four active isozymes of PADs (i.e. PAD1-4) by covalent modification 
of the active site of the enzymes.  Our previous studies have shown that Cl-amidine 
effectively suppresses inflammation and oxidative stress associated with ulcerative colitis 
and prevents tumorigenesis of colitis-associated colon cancer (12, 13).  Based on our 
results, we proposed a cancer preventative mechanism of action of Cl-amidine involving 
the upregulation of the well-studied tumor suppressor microRNA (miRNA), miR-16, and 
the subsequent downregulation of its cell cycle targets, Cyclin D1 and E1 (13-17).  A 
microarray analysis of miRNAs revealed that only a small subset of miRNAs are affected 
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by Cl-amidine, instead of global miRNA regulation (14).  The aim of our current study is 
to understand how Cl-amidine is targeting select miRNAs, like miR-16.   
Epigenetic regulation of genes has entered the spotlight recently as methylation and 
other modifications to DNA and histones have become more studied.  DNA methylation is 
catalyzed by a family of enzymes called the DNA methyltransferases (DNMTs).  The 
enzymatically active members of the DNMT family include an abundant maintenance 
methyltransferase, DNMT1, and de novo methyltransferases, DNMT3A and DNMT3B.  
DNMTs regulate genes by methylating CpG islands located in the promoter regions, while 
aberrant hypermethylation can trigger methylation-mediated gene silencing of targeted 
genes and even miRNAs.  DNMT hyperactivity and tumor suppressor miRNA 
downregulation are both associated with various cancers (18-21).  For example, the 
promoter of the tumor suppressor miR-200b can be hypermethylated by DNMT1 and, 
subsequently, the loss of miR-200b expression results in tumorigenesis (21).  We 
hypothesize that a similar mechanism, initiated by abnormal DNMT activity, is resulting 
in the hypermethylation of the miR-16 promoter and is causing its suppression in cancer.  
Abnormal DNMT activity may be due to citrullination since DNMT3A has been reported 
to be a citrullinated target of PAD4, which promoted elevated levels of methylation (22).  
 The connection between citrullination and methylation-mediated gene silencing has 
been considerably under studied, but our data links DNMT citrullination and inhibition to 
the regulation of miR-16.  Our current study demonstrates a novel epigenetic facet of Cl-
amidine and provides further insight into the complex pathways that are involved in cancer 
progression. 
 
  
126 
 
5.2 MATERIALS AND METHODS 
5.2.1 CL-AMIDINE 
The synthesis of Cl-amidine has previously been described (23, 24). 
5.2.2 CELL CULTURE AND TREATMENT 
The isogenic human colorectal carcinoma cell lines, HCT116 wild-type (wt),  
DNMT1 -/-, and DNMT3B -/- (see Figure 5.1 for cell line verification), were maintained 
in McCoy’s 5A media (ATCC) supplemented with 10% fetal bovine serum (Life 
Technologies), penicillin (10 U/mL) and streptomycin (10 µg/mL; Mediatech).  To inhibit 
citrullination, HCT116wt cells were treated with 50 µM Cl-amidine for 12 hours.  For 
experiments involving 5-Azacytidine (5-Aza; Sigma-Aldrich), cells were treated with 10 
µM 5-Aza for 24 hours.  During the 24 hour treatment, media was changed and replenished 
with fresh 5-Aza every 12 hours. 
5.2.3 WESTERN BLOT ANALYSIS AND ANTIBODIES 
Western blots were performed as previously described (25).  The following 
antibodies were used: α-peptidyl-citrulline (clone F95) (mouse monoclonal, diluted 1:100; 
EMD Millipore), DNMT1 (rabbit monoclonal, diluted 1:500; Cell Signaling), DNMT3A 
(rabbit polyclonal, diluted 1:500; Abcam), DNMT3B (mouse monoclonal, diluted 1:500; 
Novus Biologicals), and GAPDH (clone 14C10) (glyceraldehyde 3-phosphate 
dehydrogenase; rabbit monoclonal, diluted 1:1000; Cell Signaling).  
5.2.4 IMMUNOPRECIPITATION 
Immunoprecipitation was performed according to Dynabeads Protein G (Life 
Technologies) product description.  Briefly, 1.5 mg of magnetic Dynabeads were bound to 
primary antibodies (DNMT1 diluted 1:50, Novus Biologicals; DNMT3A diluted 1:50, 
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Abcam; DNMT3B diluted 1:50, Novus Biologicals) for 1 hour at room temperature while 
rocking.  The bead-antibody complex was washed with 1x PBST and then incubated with 
whole cell protein lysate at room temperature for 1 hour while rocking.  Next, the bead-
antibody-antigen complex was washed again and resuspended in SDS Loading Buffer (5% 
β-mercaptoethanol; Life Technologies).  To remove the beads from the complex, the 
samples were boiled for 10 minutes. 
5.2.5 QUANTITATIVE REAL-TIME PCR 
5.2.5.1 MEASURING MIRNA EXPRESSION 
Total miRNA was extracted from HCT116wt, DNMT1 -/-, and DNMT3B -/- cells 
according to miRNeasy Mini Kit instructions (Qiagen).  Quantification of RNA 
concentration and stability were determined by Nanodrop 2000 (Nanodrop, Wilmington, 
DE).  To reverse transcribe 10 ng of total RNA into cDNA, we used the TaqMan 
MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to 
kit instructions.  Primers used include hsa-miRNA-16 for miR-16 detection and small 
nuclear protein RNU6B (U6) for normalization (Applied Biosystems, Foster City, CA).  
Quantitative Real-Time PCR was performed using the TaqMan miRNA Assay (Applied 
Biosystems, Foster City, CA) with the 7300 PCR Assay System (Applied Biosystems, 
Foster City, CA).  The relative fold change (FC) of miR-16 expression, as compared to U6 
expression, was determined based on the comparative threshold cycles (Ct) of miR-16 and 
U6.  Experiments were performed at three separate times and each sample was analyzed in 
triplicate. 
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5.2.5.2 MEASURING MRNA EXPRESSION 
 RNA was extracted from HCT116wt cells (untreated or treated with 50 µM Cl-
amidine for 12h) according to RNeasy Mini Kit instructions (Qiagen).  RNA concentration 
and stability were measured as described in the previous section.  1 µg of total RNA was 
used to make cDNA using the Promega Reverse Transcription Kit (Promega Corp, WI) 
according to kit instructions.  The human primer sequences used for Real-Time PCR were: 
DNMT1 Forward 5’-GAG CTA CCA CGC AGA CAT CA-3’, DNMT1 Reverse 5’-CGA 
GGA AGT AGA AGC GGT TG-3’, DNMT3A Forward 5’-GCC TCA ATG TTA CCC 
TGG AA-3’, DNMT3A Reverse 5’-CAG CAG ATG GTG CAG TAG GA-3’, DNMT3B 
Forward 5’-CCC ATT CGA GTC CTG TCA TT-3’, DNMT3B Reverse 5’-GGT TCA 
CAA CAG CAA TGG ACT-3’, GAPDH Forward 5’-GAG TCA ACG GAT TTG GTC 
GT-3’, and GAPDH Reverse 5’-GAC AAG CTT CCC GTT CTC AG-3’ (Integrated DNA 
Technologies, Inc.).  Quantitative Real-Time PCR was performed using the 7300 Real-
Time PCR Assay System (Applied Biosystems, CA) with Power SYBR green PCR master 
mix (Applied Biosystems, CA) and primers for DNMT1, DNMT3A, DNMT3B, and 
GAPDH.  GAPDH gene expression was used for normalization versus DNMT1, 
DNMT3A, and DNMT3B.  The fold change of DNMT1, DNMT3A, and DNMT3B mRNA 
expression, as compared to GAPDH mRNA expression, was determined based on the 
comparative Ct values.  Experiments were performed at three separate times and each 
sample was analyzed in triplicate. 
5.2.6 DNA EXTRACTION AND BISULPHITE CONVERSION 
Genomic DNA (gDNA) was extracted from HCT116wt cells according to Quick-
gDNA MiniPrep kit instructions (Zymo Research).  To ensure adequate DNA extraction, 
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DNA concentrations and stability were measured using Nanodrop 2000.  Then, 1 µg of 
gDNA was bisulphite converted using EZ DNA Methylation-Gold Kit (Zymo Research) 
according to kit instructions.   
5.2.7 METHYLATION-SPECIFIC PCR 
PCR was performed using eluted bisulphite-converted DNA and methylation-
specific PCR primers.  The sequences for methylated- and unmethylated-specific primers, 
as designed with MethPrimer (26), were as follows: Methylated Forward 5’-GGA TAG 
GTT ATT TTG TTT TTT TCG T-3’, Methylated Reverse 5’-CCG ACA TTC CCT AAA 
ACG AC-3’, Unmethylated Forward 5’-GGA TAG GTT ATT TTG TTT TTT TTG T-3’, 
Unmethylated Reverse 5’-TTC CCA ACA TTC CCT AAA ACA-3’ (Integrated DNA 
Technologies, Inc.).  The methylation-specific PCR primers were designed to target a miR-
16 promoter region near the transcriptional start site of DLEU2 gene (27).  To analyze the 
methylation status of the targeted miR-16 promoter region, we performed conventional 
PCR.  Briefly, ZymoTaq PreMix (Zymo Research) polymerase mastermix was mixed with 
corresponding forward and reverse primers (1 µM final concentration), 150 ng of 
bisulphite-converted DNA template, and nuclease-free water.  After conventional PCR, we 
ran the PCR products on a 1.5% agarose gel with ethidium bromide.  Bands were captured 
under UV light. 
5.2.7 STATISTICAL ANALYSIS 
Mean differences between groups were compared by Student’s T-test. The p-value 
chosen for significance in this study was 0.05. 
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5.3 RESULTS 
5.3.1 CL-AMIDINE INHIBITS PROTEIN CITRULLINATION AND 5-AZACYTIDINE INHIBITS 
DNMTS 
Protein citrullination has various physiological effects on gene regulation, 
apoptosis, and structural support; however, under disease conditions, off-target and 
excessive citrullination can occur (1, 5, 10, 28-30).  Aberrant citrullination can result in 
loss of function, reduced function, or even hyperactivity of a protein. We have shown that 
Cl-amidine, a pan-PAD inhibitor, decreases peptidyl-citrulline levels in a dose-dependent 
manner (Figure 5.1C).  Our previous studies have also shown that Cl-amidine, at a dose 
comparable to 50 µM, increases miR-16 expression in HCT116wt cells (14).  Interestingly, 
Cl-amidine was found to alter the expression of only 18 miRNAs in a microarray analysis 
(14), suggesting that Cl-amidine is not targeting global miRNA expression.   
In order to understand how Cl-amidine is selectively affecting certain miRNAs, we 
investigated a potential epigenetic mechanism of action involving DNMTs.  DNMTs (i.e. 
DNMT1, DNMT3A, and DNMT3B) are key regulators of gene expression and can cause 
methylation-mediated gene silencing in certain instances of hypermethylated gene 
promoters (31).  To decipher the effects of DNMT activity in our study, we used 5-Aza, a 
DNMT inhibitor.  We saw optimal DNMT inhibition at a concentration of 10 µM for 24h 
(Figure 5.1D). 
5.3.2 DNMT1 IS CITRULLINATED 
To verify that DNMTs can be post-translationally citrullinated, we performed 
immunoprecipitation to isolate individual DNMTs and probed for peptidyl-citrulline.  The 
presence of peptidyl-citrulline in untreated HCT116wt cells indicates that isolated DNMT1 
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(Figure 5.2A) is citrullinated.  Interestingly, DNMT3A and DNMT3B do not appear to be 
citrullinated (Figure 5.2B and C).  Although research concentrating on the citrullination of 
DNMTs is limited, our findings contradict the article by Deplus et al. which found 
DNMT3A to be citrullinated by PAD4 (22).  However, it is important to note that different 
cell lines were used and DNMT1 and DNMT3B were not examined in previous 
experiments (22). 
5.3.3 INHIBITION OF DNMTS RESCUES SUPPRESSION OF MIR-16 
Since the citrullination of DNMT1 has been validated (Figure 5.2A), we observed 
the effects of Cl-amidine and 5-Aza treatments on miR-16 levels.  Our group has previously 
shown that Cl-amidine significantly upregulated miR-16 expression in vitro and in vivo 
(13, 14).  Citrullination can alter protein activity (22, 32, 33) and Deplus et al. specifically 
showed that the citrullination of DNMT3A resulted in hypermethylation (22).  
Furthermore, hypermethylation of gene promoters can lead to methylation-mediated gene 
silencing (31).  To determine if Cl-amidine is working by preventing methylation-mediated 
gene silencing of miR-16, we must first consider if the inhibition of DNMTs, by 5-Aza 
treatment, is sufficient to increase miR-16 expression.  In fact, our results reveal that 5-Aza 
treatment significantly increased miR-16 expression to a level comparable to Cl-amidine 
treatment (Figure 5.3A), possibly by similar regulation of DNMTs. 
To further delineate which of the DNMTs is/are responsible for miR-16 
suppression, we measured miR-16 expression in HCT116wt versus HCT116 DNMT1-/- 
and HCT116 DNMT3B-/- cell lines.  miR-16 expression was significantly upregulated, as 
compared to levels in HCT116wt, only in HCT116 DNMT1-/- cells (Figure 5.3B).  This 
finding indicates that DNMT1 is the DNMT essential for modulating miR-16 expression.  
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Furthermore, DNMT1 gene expression is significantly more abundant than DNMT3A and 
DNMT3B (Figure 5.3C), making its regulation of greater interest and consequence.    
5.3.4 METHYLATION OF THE MIR-16 PROMOTER 
miR-16 is a putative tumor suppressor miRNA with various cell cycle targets (14-
17, 34) and is frequently deleted or suppressed in various cancers.  For instance, in chronic 
lymphocytic leukemia (CLL), miR-16 and its host gene, DLEU2, are frequently deleted 
(35); whereas, in breast and colon cancer, miR-16 is often downregulated (36-38).  Based 
on our results thus far, our hypothesis is that miR-16 is being epigenetically downregulated 
in colon cancer by the hypermethylation of its promoter.  To test this theory, we extracted 
gDNA from HCT116wt samples for bisulphite conversion.  Then, using methylated and 
unmethylated primers, we performed methylation-specific PCR targeting the promoter 
sequence of miR-16 on its host gene, DLEU2 (Figure 5.4A).  We found that Cl-amidine 
(50 µM for 12h) and 5-Aza (10 µM for 24h) decreased the expression of the methylated 
miR-16 promoter as compared to the untreated HCT116wt cells (Figure 5.4B).  In 
accordance with our hypothesis, we see that Cl-amidine reduces methylation of the miR-
16 promoter, indicating that Cl-amidine works to rescue miR-16 expression by alleviating 
the methylation-mediated silencing caused by hyperactive DNMTs. 
5.4 DISCUSSION 
As we show in our current study, citrullination occurs in DNMT1, but not 
DNMT3A and DNMT3B (Figure 5.2).  The selectivity towards citrullinated DNMT1 could 
be due to the shear abundance of DNMT1 as compared to DNMT3A and DNMT3B in the 
cell or more potential sites of citrullination (i.e. more arginine residues present).  We also 
see that DNMT inhibition causes an increase in the tumor suppressor miR-16, similar to 
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the rescue of miR-16 seen in Cl-amidine-treated cells (Figure 5.3A).  Thus, our results 
indicate that Cl-amidine may indeed be acting to regulate DNMTs as well.  We found that 
DNMT1 inhibition alone was able to restore miR-16 expression (Figure 5.3B).  Since 
DNMT1 has higher basal expression than DNMT3A and DNMT3B (Figure 5.3C), the 
importance of its hypothesized role in the epigenetic regulation of miR-16 is amplified.  
Finally, we establish that the methylation status of the miR-16 promoter is inversely related 
to miR-16 expression, as Cl-amidine and 5-Aza caused reduced promoter methylation 
(Figure 5.4B) and increased miR-16 expression (Figure 5.3A).  
Epigenetic regulation of genes has proven to have a substantial effect on tumor 
initiation, progression, and metastasis.  A major focus of epigenetic studies is the 
modification of DNA and histones.  Methylation is a well-studied epigenetic factor that 
can alter gene expression with as little as the addition or removal of methyl groups on a 
histone or DNA (31, 39).  Another factor that is emerging as an epigenetic modulator is 
citrullination.  Citrullination has been reported by many researchers to target histones (40-
44), but more recently, only a single study has been published to indicate DNMTs 
(specifically DNMT3A) can also be targeted by PADs (22).  Based on our previously 
published data implicating that Cl-amidine can increase expression of several tumor 
suppressor miRNAs and can prevent UC-associated CRC (13, 14), we decided to further 
explore the effects of DNMT citrullination in our human colorectal cell line.  To date, our 
group is the first to indicate that Cl-amidine may be able to rescue miRNA expression 
through the regulation of DNMT activity.  Since the majority of genes are targets of 
miRNAs (45), our work provides a novel pathway connecting PAD inhibition with 
downstream DNMT regulation to alleviate methylation-mediation gene silencing. 
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Collectively, our findings support the hypothesis that Cl-amidine upregulates miR-
16 expression by inhibiting the citrullination and hyperactivity of DNMTs, which in turn 
eliminates methylation-mediated silencing of miR-16 (Figure 5.5).  Results from this study 
reveal the effects of Cl-amidine on the promoter methylation activity of DNMTs.  Overall, 
the potential for Cl-amidine as a drug to prevent colitis-associated colorectal cancer is 
strengthened by our study which reveals an innovative mechanism of epigenetic regulation 
by Cl-amidine.  
5.5 FUTURE EXPERIMENTS AND RATIONALE  
In our current study, we reported that DNMT1 is key to inhibiting miR-16 
expression (Figure 5.3B).  However, we do not have a cell line that is DNMT3A deficient 
and, therefore, cannot rule out that DNMT3A may also be essential to regulating 
methylation-mediated silencing.  To solve this problem, we could use siRNA to 
individually knockdown DNMT1, DNMT3A, and DNMT3B.  Using siRNA would allow 
us to investigate the individual roles that all 3 major DNMTs (DNMT1, DNMT3A, and 
DNMT3B) have on miR-16 expression.  Moreover, to further substantiate our current 
results showing that Cl-amidine is reducing DNMT hyperactivity [i.e. miR-16 
downregulation (Figure 5.3A) and hypermethylation of miR-16 promoter (Figure 5.4B)], 
we propose to treat siRNA knock down cells with Cl-amidine and then measure total 
methylation using an ELISA-based methylation assay kit (Epigentek).  This assay kit uses 
a colorimetric reaction to quantify total 5-methylcytosine (5-mC) content in gDNA 
samples.  Results from this experiment will determine if Cl-amidine significantly inhibits 
hypermethylation through the regulation of one or more DNMTs. 
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This study could also be extended to other miRNAs that we have shown to be 
upregulated by Cl-amidine in vitro (e.g. miR-200b, let-7a, miR-19b) (14).  To look at these 
other miRNAs, we would need to design unmethylated- and methylated-specific primers 
for a promoter sequence for each of these miRNAs in a similar fashion to how the miR-16 
methylation-specific primers were designed (Figure 5.4).  Then, using bisulphite-converted 
gDNA, we could compare the promoter methylation of each of these miRNAs for 
untreated, Cl-amidine-treated, and 5-Aza-treated samples [same method as we completed 
for miR-16 methylation-specific PCR (Figure 5.4B)].  If Cl-amidine is increasing miRNA 
levels by inhibiting promoter hypermethylation, then we would expect to see the 
methylation of these miRNA promoters decreased too.  Furthermore, to validate that Cl-
amidine is not inhibiting promoter methylation in all miRNAs, we could use methylation-
specific primers for miRNAs whose expression was not significantly altered by Cl-amidine 
(14).  For example, we could use tumor suppressor miRNAs (i.e. miR-29b, miR-143, and 
miR-145) that have been shown to be downregulated in colon cancer (46-49), but were not 
found to be regulated by Cl-amidine treatment in our microarray (14).  Results from this 
experiment would also provide evidence that Cl-amidine is not affecting global miRNA 
expression.  Ultimately, these additional experiments are proposed to strengthen our 
current in vitro study and to lay the ground work for future in vivo studies exploring the 
epigenetic regulation by Cl-amidine in animal models.  
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Figure 5.1. Cell line and treatment verification. DNMT mRNA (A) and protein (B) 
expression in HCT116 DNMT1-/- and DNMT3B-/- cell lines as measured by qPCR and 
Western Blot analysis, respectively.  C) Cl-amidine inhibits peptidyl-citrulline expression 
in a dose-dependent manner and optimally for our experiments at 50 µM for 12h in 
HCT116wt.  D) 5-Aza inhibits DNMT1, DNMT3A, and DNMT3B expression at 10 µM 
for 24h in HCT116wt.   
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Figure 5.2.  The citrullination of DNMTs.  DNMT1 (A), but not DNMT3A (B) and 
DNMT3B (C), is shown to be citrullinated.  Citrullination of immunoprecipitated DNMTs 
was measured by probing with peptidyl-citrulline antibody.  The immunoprecipitation 
control (No 1° Ab) indicates samples that were incubated with IP beads without bound 
primary antibody. 
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Figure 5.3.  The effects of DNMT inhibition and knockout on miR-16 expression.  A)  
5-Azacytidine treatment (10 µM for 24h) increases miR-16 expression to levels 
comparable to after Cl-amidine treatment (50 µM for 12h) in HCT116wt cells.  B) miR-16 
expression is increased in HCT116 DNMT1-/-, but not HCT116 DNMT3B-/- cells, as 
compared to HCT116wt cells.  C) DNMT1 gene expression is substantially more abundant 
than DNMT3A and DNMT3B in HCT116wt cells.  Significant differences from the 
Untreated (A), WT (B), or hDNMT1 (C) samples are indicated by * (p<0.05).  
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Figure 5.4.  The effect of Cl-amidine on the methylation status of the miR-16 
promoter.  A) The nucleotide sequence (50,655,989-50,656,271) is a truncated, yet active, 
DLEU2 promoter sequence (27).  The promoter sequence also occurs within a CpG island 
(50,655,070-50,656,564); therefore, this sequence can be used to build methylation-
specific PCR primers for the promoter of DLEU2/miR-16.  Using the MethPrimer online 
tool and database (26), this promoter sequence can be entered to get sets of Unmethylated- 
and Methylated-specific PCR primers.  The nucleotide at the transcriptional start site of 
DLEU2 is highlighted in green.  B) Sets of unmethylated (U; 130bp) and methylated (M; 
127bp) primers were used to observe the methylation status of the miR-16 promoter in 
untreated HCT116wt cells versus cells treated with 50 µM Cl-amidine for 12h or 10 µM 
5-Aza for 24h.  Based on the intensity of the bands, samples treated with Cl-amidine and 
5-Aza both seem to reduce the expression of the methylated miR-16 promoter as compared 
to the untreated samples.  The DNA ladder indicates 100bp at each band.  
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Figure 5.5.  Proposed model of the epigenetic regulation of miR-16 by Cl-amidine.  
Our results demonstrate that the inhibition of DNMT citrullination/subsequent 
hyperactivity can rescue miR-16 expression in HCT116 colon cancer cells.  The resulting 
increase in miR-16 expression is due to the reduced methylation levels found at the miR-
16 promoter after Cl-amidine treatment.  The restored expression of once silenced (by 
methylation) tumor suppressor miRNAs will downregulate oncogenic targets and will 
ultimately prevent the initiation of carcinogenesis. 
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CHAPTER 6 
MECHANISM OF ACTION FOR INHIBITION OF PAD-RELATED COLORECTAL CANCER: 
CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 SUMMARY AND CONCLUSIONS 
 In Chapter 3, we showed that Cl-amidine was able to reduce inflammatory markers, 
iNOS and Cox-2, and oxidative stress in the ANA-1 murine macrophage cell line.  
Meanwhile, in a pro-inflammatory environment, DNA damage was inhibited by Cl-
amidine in the HCT116wt colon cancer cell line.  We then turned to an in vivo model of 
colitis.  In the AOM/DSS mouse model of ulcerative colitis (UC), we were able to 
corroborate similar results from our in vitro experiments, demonstrating that our cellular 
models of inflammation are adequate for initial studies and are translatable to our animal 
model (1).   
Building off of our success in Chapter 3, we followed the pathological progression 
from UC to colorectal (CRC) and thus expanded our research focus to include studying Cl-
amidine as a prospective cancer preventative.  Initial in vitro results brought the importance 
of tumor suppressor miRNAs, mainly miR-16, into the picture.  In Chapter 4, we reported 
that miR-16 was upregulated by Cl-amidine and caused subsequent G1 cell cycle arrest in 
vitro.  We also performed PAD4 and miR-16 knock downs to verify that the outcomes seen 
with Cl-amidine treatment are indeed occurring as a direct result of PAD4 inhibition and 
that G1 cycle arrest is being mediated by miR-16.  These findings set the foundation for 
our in vivo model of UC-associated CRC.  Since miR-16 expression was correspondingly 
upregulated by Cl-amidine in vitro and in vivo, we were once again able to validate our 
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cellular results in our animal model.  Results from Chapter 4 establish that Cl-amidine is 
not only a prospective colitis treatment, but it also is favorable as a UC-associated CRC 
preventative as seen in the suppressed tumorigenesis and upregulation of tumor suppressor 
miR-16 (2). 
 We took an epigenetic approach in Chapter 5 to answer the lingering question of 
why Cl-amidine is only influencing a small subset of miRNAs instead of global miRNA 
expression.  Based on previous reports, we developed the hypothesis that DNA 
methyltransferase (DNMT) dysregulation is responsible for methylated-mediated silencing 
of targeted genes.  In Chapter 5, we determined that DNMT inhibition and Cl-amidine are 
able to equally rescue miR-16 expression in vitro.  Additionally, we showed that miR-16 
expression can be increased by DNMT1 inhibition alone, making DNMT1 expression and 
activity of the greatest significance in our current epigenetic study.  Cl-amidine also was 
capable of reducing the methylation of the miR-16 promoter by preventing dysregulated 
DNMT activity.  Based on our results, we explain that the selectivity of Cl-amidine to 
regulate only certain miRNAs is based off of each miRNA promoter’s susceptibility to 
hypermethylation and silencing.  The results from Chapter 5 implicate PADs/citrullination 
as a modulator of DNMT activity with subsequent silencing of genes involved in an array 
of pathways; hence, explaining how Cl-amidine can regulate a multitude of cellular 
responses to suppress pro-inflammatory pathogenesis and tumorigenesis. 
With the findings presented in this dissertation, we have shown that Cl-amidine is 
in fact an effective anti-inflammatory compound with anti-oxidant properties.  Cl-amidine 
likewise protects epithelial cells from DNA damage and successfully prevents the 
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progression from UC to CRC.  We see that Cl-amidine influences many different processes, 
which reflects the myriad of pathways also modulated by PAD activity.   
6.2 FUTURE DIRECTIONS 
 We have successfully uncovered the role of Cl-amidine in numerous pathways, 
including regulatory effects on ROS production, anti-oxidant enzyme expression, miRNA 
expression, cell proliferation, and epigenetics through the use of various in vitro and in vivo 
models.  Due to its minimal toxicity and anti-inflammatory, anti-oxidant, and anti-cancer 
properties, Cl-amidine has a very promising potential as a therapeutic and preventative 
against UC and CRC.  Future studies can continue testing the efficacy of Cl-amidine in 
other species, as well as investigating the roles of p53- and miR-16-dependence in animal 
models.  Our group plans to utilize mouse models with genes of interest knocked out.  We 
propose using miR-16 knockout (KO) mice to reveal the importance of miR-16 in the 
effectiveness of Cl-amidine to prevent UC-associated CRC.  miR-16 KO mice have been 
generated by other labs and are commercially available (3); however, these mice have not 
been subjects of colitis-induced colorectal cancer models, making our future work 
groundbreaking. 
Additionally, we can knock out PADs, specifically PAD4, to show that Cl-amidine 
is working directly through PAD inhibition and that PADs are important for the 
pathogenesis of UC.  Currently PAD4 KO mice have been established, but have been used 
to study rheumatoid arthritis, hematopoietic cells, and non-small cell lung cancer (4-6).  
Using the PAD4 KO mice to study ulcerative colitis and the progression to colorectal 
cancer would be a novel and innovative contribution to broaden the understanding of the 
role of PADs in this inflammatory disease. 
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Furthermore, future studies will be conducted using the more potent and 
bioavailable second generation compound, BB-Cl-amidine.  BB-Cl-amidine has been 
shown to be about 20 times more potent than Cl-amidine with a lower EC50 (7), but still 
acts through PAD inhibition to yield similar regulation of pathways also targeted by Cl-
amidine.  Our current results and future projects will promote the overall understanding of 
Cl-amidine, and related compounds, and are ultimately aimed at the development of these 
compounds to help millions of people around the world who are affected by UC and UC-
associated CRC.  
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